FROM EVIDENCE TO PRACTICE IN - ecco-org.eu/media/Documents/ECCO sections/Amsterdam... · FROM EVIDENCE TO PRACTICE IN MULTIDISCIPLINARY CANCER CARE. 2. ECCO2017 - rom Evidence to

1ECCO2017 - From Evidence to Practice in Multidisciplinary Cancer Care - Advance Programme eccocongress.org

eccocongress.org

FROM EVIDENCE TO PRACTICE IN MULTIDISCIPLINARY CANCER CARE

2 ECCO2017 - From Evidence to Practice in Multidisciplinary Cancer Care - Advance Programme eccocongress.org 3ECCO2017 - From Evidence to Practice in Multidisciplinary Cancer Care - Advance Programme eccocongress.org

IMPORTANT DEADLINES

Abstract Submission Opens 25 Apr 2016

Early Registration Deadline

Abstract Submission Deadline 25 Aug 2016

Fellowship Application Deadline 30 Aug 2016

Late-Breaking Abstract Submission Opens 23 Nov 2016

Regular Rate Deadline 28 Nov 2016

Late-Breaking Abstract Submission Deadline 7 Dec 2016

ECCO2017 European Cancer Congress 27-30 Jan 2017

Welcome to ECCO2017 – European Cancer Congress, the multidisciplinary evidence based meeting for all cancer types, addressing all oncology disciplines and related healthcare professions. ECCO2017 will have a direct impact on daily clinical practice.

Peter Naredi

President European CanCer Organisation (ECCO)

CHAIR'S INTRODUCTION

Focusing on phase III data, this scientific meeting will put the new evidence into perspective for a multidisciplinary audience by critically reviewing it in expert panels. Leading oncologists will address the value of these potentially practice changing treatments by reviewing their clinical benefits and cost. Experts, patient advocates and the audience will determine whether the data really do support changes in clinical practice.

Recognising the discrepancies between what happens in real life and in a clinical trial setting, the congress will give centre stage to real world data showing the impact on treatment and care.

This focus on clinical practice will give delegates concrete, up-to-date knowledge through a multidisciplinary tumour board format, and give them the opportunity to participate in identifying practice - changing developments.

The Educational Committee has prepared a comprehensive educational programme covering topics from using evidence-based information to guide decisions on treatment options to understanding health economics and outcome research. There will be a strong focus on immunotherapy and personalised medicine.

Based on ground-breaking research, the programme will also look at evolving healthcare systems and the future of cancer treatment, with particular regard to access to innovation, disparities in cancer care and the diminishing oncology workforce. Given the increasing role that primary care looks set to play in secondary cancer care, ECCO2017 will invite community care physicians, oncologists and patient advocates to discuss this evolution.

Regulatory sessions on newly approved drugs and innovation in local regional treatment will gather regulators, HTA bodies, academia, industry and patient advocates.

ECCO2017 will shed light on ECCO policy initiatives, centred around the oncology workforce and quality cancer care, making sure cancer is at the top of the EU public health agenda.

In addition to designing dedicated advocacy sessions, the ECCO Patient Advisory Committee has contributed its essential insights into the scientific programme. During the congress, its members will play a key role in reviewing innovations from the most important perspective – that of the patients they aim to help.

ECCO is an open forum for its members. The first day of ECCO2017 will feature societies’ meetings for their members and the oncology community: the European Oncology Nursing Society (EONS), the European Organisation for Research and Treatment of Cancer (EORTC), the European School of Oncology (ESO), the European Society of Surgical Oncology (ESSO), the European SocieTy for Therapeutic Radiology and Oncology (ESTRO), and the European Society for Paediatric Oncology (SIOPE).

Reaching a global audience, ECCO2017 has an extensive media programme for scientific media worldwide. Submitting your practice changing data for presentation at ECCO2017 will ensure its global visibility.

We thank ECCO member societies, the ECCO Patient Advisory Committee, and leading experts, for designing this innovative scientific programme.

ECCO2017 will change the paradigm of oncology, be part of this change!

Peter Naredi Congress Chair Ian Banks Congress Co-ChairMichael Baumann Scientific Chair Ian Tannock Educational Committee ChairMichel Wouters National Organising Committee Chair

2 7 Aug 2016


ECCO MEMBERS

ECCO represents and serves the interests of over 80 000 professionals in oncology through its 23 Member Organisations. It provides a cohesive platform for European Cancer Societies and Organisations with the aim to work together to improve cancer patient outcomes, and to be the unified voice of the European cancer community when addressing common policy issues.

OFFICIAL MEDIA PARTNERS

The Organising Committee gratefully acknowledges the collaboration and support of our official media partners for the European Cancer Congress ECCO2017:

ACKNOWLEDGEMENTS

ECCO MEMBER SOCIETIES

PRIMARY CARE SESSIONS

The Organising Committee thanks ECCO member societies for their contribution to the development of the ECCO2017 innovative scientific programme.

The Organising Committee gratefully acknowledges the contribution of these organisations to the development of the Primary Care Sessions:

EANO


/Disseminating Research/Advancing Care/Improving Lives

Where cancer researchers and oncologists find the latest peer-reviewed research and reviews.A convenient one-stop resource that:• announceslatestArticles-in-PressfromElsevier’scomprehensive portfolioofOncologyjournals• providesaccesstotheneweditionsandarchiveoftheEJCNewsFocusupdates• transmitsfreePodcastsfromleadingpublications• keepsyouinformedonindustrymeetingsandevents• andmuchmore…

Visit OncologyAdvance.com today.ONECLICKACCESSTOESSENTIALRESOURCESINONCOLOGY

CONGRESS COMMITTEES


EUROPEAN CANCER CONGRESS 2017 COMMITTEES

SCIENTIFIC MEMBERS

Regina Beets Tan Lifang Liu

Martin Gore Kathy Oliver

Maarten IJzerman Richard Sullivan

Bengt Jönsson Elisabeth de Vries

Valery Lemmens Chris Wild

Yolande Lievens

Michel Wouters – National Organising Chair

Martin van den Bent Kees Punt

Inne Borrel Rinkes Franz Schramel

Guus van Dongen Hermien Schreurs

Hans Gelderblom Ludi Smeele

Koos van der Hoeven Kristien Tytgat

Philip Kluin Marcel Verheij

Jeroen van Moorselaar Michel Versteegh

Hans Nijman Hans de Wilt

Ian Tannock – Educational Committee Chair

Riccardo Audisio Fedro Peccatori

Leticia De Mattos-Arruda Martine Piccart

Jesper Eriksen Rebecca Verity

Dow-Mu Koh

EUROPEAN CANCER CONGRESS 2017 COMMITTEES

NATIONAL ORGANISING COMMITTEE

EDUCATIONAL COMMITTEE

Peter Naredi Congress Chair

Ian Banks Congress Co-Chair

Michael Baumann Scientific Chair

Martine Piccart ECCO Past President

Vincent Gregoire ECCO Treasurer

Michel Wouters National Organising Chair

ORGANISING COMMITTEE

Alain Astier Robert Mansel

Laura Biganzoli Francesco Montorsori

David Cameron Gunnar Sater

Franco Cavalli Martin Schrappe

Leticia De Mattos-Arruda Lena Sharp

Stefan Fanti Martin Taphoorn

Winette van der Graaf Emmanuel Tiret

Santiago Gonzalez-Moreno Luzia Travado

Rüdiger Greinert Vincenzo Valentini

Ilmo Leivo

SCIENTIFIC AND SOCIETY LIAISON COMMITTEE

SOCIETY LIAISON MEMBERS

CONGRESS CORE COMMITTEE

Michael Baumann – Scientific Chair Francesco Montorsi

Ian Banks Peter Naredi

Renzo Canetta Wim Oyen

Elisabeth Eisenhauer Martine Piccart

Daniel Kelly Cornelis van de Velde

Denis Lacombe


PROGRAMME OVERVIEW

PR

OG

RA

MM

E O

VE

RV

IEW

LEAD

ERSH

IPPR

OGR

AMM

E I

08:0

0-12

:00

LEAD

ERSH

IPPR

OGR

AMM

E II

14:3

0-17

:00

ESTR

O S

OCI

ETY

PRO

GRAM

ME

SATE

LLIT

E SY

MPO

SIA

ESTR

O S

OCI

ETY

PRO

GRAM

ME

SATE

LLIT

E SY

MPO

SIA

ESTR

O S

OCI

ETY

PRO

GRAM

ME

SATE

LLIT

E SY

MPO

SIA

ESTR

O S

OCI

ETY

PRO

GRAM

ME

SATE

LLIT

E SY

MPO

SIA

EORT

C SO

CIET

YPR

OGR

AMM

E

SATE

LLIT

E SY

MPO

SIA

EORT

C SO

CIET

YPR

OGR

AMM

E

SATE

LLIT

E SY

MPO

SIA

WH

AT A

N O

NCO

LOGI

ST

CAN

LEA

RN F

ROM

AN

IM

AGIN

G SP

ECIA

LIST

SATE

LLIT

E SY

MPO

SIA

TO B

E AN

NO

UN

CED

SATE

LLIT

E SY

MPO

SIA

SIO

PE S

OCI

ETY

PRO

GRAM

ME

SIO

PE S

OCI

ETY

PRO

GRAM

ME

SATE

LLIT

E SY

MPO

SIA

EON

S SO

CIET

YPR

OGR

AMM

E

EON

S SO

CIET

YPR

OGR

AMM

E

SATE

LLIT

E SY

MPO

SIA

ESSO

SO

CIET

YPR

OGR

AMM

E

ESSO

SO

CIET

YPR

OGR

AMM

E

SATE

LLIT

E SY

MPO

SIA

ESSO

SO

CIET

YPR

OGR

AMM

E

ESSO

SO

CIET

YPR

OGR

AMM

E

SATE

LLIT

E SY

MPO

SIA

IND

UST

RY S

POTL

IGH

T SE

SSIO

NS

(09:

30-1

0:30

)

IND

UST

RY S

POTL

IGH

T SE

SSIO

NS

(11:

00-1

2:00

)

IND

UST

RY S

POTL

IGH

T SE

SSIO

NS

(13:

30-1

4:30

)

IND

UST

RY S

POTL

IGH

T SE

SSIO

NS

(16:

30-1

7:30

)

IND

UST

RY S

POTL

IGH

T SE

SSIO

NS

(15:

00-1

6:00

)

FR

IDA

Y 2

7T

H J

AN

UA

RY

20

17

12 13

PR

OG

RA

MM

E O

VE

RV

IEW

SA

TU

RD

AY

28

TH J

AN

UA

RY

20

17

Bre

ast

CN

S E

duca

tion

al L

ymph

oma

Neu

roen

docr

ine

Pri

mar

y Ca

re S

arco

mas

Cha

ngin

g Pr

acti

ce S

essi

on C

olor

ecta

l G

ynae

colo

gy I

ndus

try

Spot

light

ses

sion

s P

allia

tive

Car

e P

oste

r vie

win

g T

hora

cic

Chi

ldho

od C

ance

rs

ECC

O S

essi

on H

ead

and

Nec

k M

elan

oma

Ple

nary

Ses

sion

Sat

ellit

e Sy

mpo

sia

Uro

logy

SU

ND

AY

29

TH J

AN

UA

RY

20

17P

RO

GR

AM

ME

OV

ER

VIE

W

Bre

ast

CN

S E

duca

tion

al L

ymph

oma

Neu

roen

docr

ine

Pri

mar

y Ca

re S

arco

mas

Cha

ngin

g Pr

acti

ce S

essi

on C

olor

ecta

l G

ynae

colo

gy I

ndus

try

Spot

light

ses

sion

s P

allia

tive

Car

e P

oste

r vie

win

g T

hora

cic

Chi

ldho

od C

ance

rs

ECC

O S

essi

on H

ead

and

Nec

k M

elan

oma

Ple

nary

Ses

sion

Sat

ellit

e Sy

mpo

sia

Uro

logy

Upp

er G

I H

aem

atol

ogy

Rare

Can

cers

Upp

er G

I H

aem

atol

ogy

Rare

Can

cers

CEN

TRAL

NER

VOU

SSY

STEM

CLIN

ICAL

SYM

POSI

UM

Glio

ma

and

Im

mun

othe

rapy

10:1

5-11

:15

CHAN

GIN

G PR

ACTI

CE

SESS

ION

Use

of E

lect

roni

c To

ols

and

Tele

med

icin

e in

O

ncol

ogy:

"The

Doc

tor

Will

Sky

pe Y

ou N

ow"

11:3

0-12

:45

POLI

CY S

ESSI

ON

II

Mee

ting

the

Chal

leng

es o

f Cr

oss-

Bord

er C

ance

r Car

e 13

:15-

14:4

5

EDU

CATI

ON

AL S

ESSI

ON

PR

OGR

AMM

E

Impr

ovin

g Pa

tien

t Saf

ety

in

Onc

olog

y15

:00-

16:3

0

CEN

TRAL

NER

VOU

SSY

STEM

CRIT

ICAL

REV

IEW

SES

SIO

NCr

itic

al R

evie

w o

f Pr

esen

ted

Tria

ls a

nd

Impl

icat

ion

in P

ract

ice

16:4

5-18

:15

SATE

LLIT

E SY

MPO

SIA

PATI

ENT

INVO

LVEM

ENT

IN

REG

ULA

TORY

DIS

CUSS

ION

S

Patie

nt In

volv

emen

t in

Regu

lato

ry D

iscu

ssio

ns

07:4

5-08

:45

CH

ANGI

NG

PRAC

TICE

SE

SSIO

N

The

Valu

e of

Can

cer R

egis

trie

s11

:30-

12:4

5

SATE

LLIT

E SY

MPO

SIA

EDU

CATI

ON

AL S

ESSI

ON

Real

Wor

ld D

ata:

Hea

lth

Out

com

es R

esea

rch

(Rep

eate

d)15

:00-

16:3

0

HAE

MAT

OLO

GY

CRI

TICA

L RE

VIEW

SES

SIO

NRe

view

of P

rese

nted

Tr

ials

and

Impl

icat

ion

in

Pra

ctic

e16

:45-

18:1

5

SATE

LLIT

E SY

MPO

SIA

NEU

ROEN

DO

CRIN

E TU

MO

URS

- RA

RE C

ANCE

RS

MD

TU

MO

UR

BOAR

D07

:45-

08:4

5

PALL

IATI

VE A

ND

SU

PPO

RTIV

E CA

RE

CLIN

ICAL

SYM

POSI

UM

Tria

ls &

Out

com

e Re

sear

ch

that

Cha

nge

Prac

tice

10:1

5-11

:15

JOIN

T EC

CO-A

SCO

SE

SSIO

N

TOPI

C TB

A11

:30-

12:4

5

SATE

LLIT

E SY

MPO

SIA

CHIL

DH

OO

DCA

NCE

RS

CLIN

ICAL

SYM

POSI

UM

Tr

ansl

atio

nal A

ppro

ache

s in

Pa

edia

tric

Onc

olog

y15

:00-

16:3

0

CHIL

DH

OO

DCA

NCE

RS

CRIT

ICAL

REV

IEW

SES

SIO

NCr

itic

al R

evie

w o

f Pr

esen

ted

Tria

ls a

nd

Impl

icat

ion

in P

ract

ice

16:4

5-18

:15

SATE

LLIT

E SY

MPO

SIA

THO

RACI

C CA

NCE

R

MD

TU

MO

UR

BOAR

D07

:45-

08:4

5

PLEN

ARY

SESS

ION

PRAC

TICE

CH

ANGI

NG

TRIA

LS II

09:0

0-11

:00

THO

RACI

C CA

NCE

R

CLIN

ICAL

SYM

POSI

UM

Tria

ls &

Out

com

e Re

sear

ch

that

Cha

nge

Prac

tice

10:1

5-11

:15

CHAN

GIN

G PR

ACTI

CE

SESS

ION

Reim

burs

emen

t and

M

arke

t Acc

ess

to

Inno

vati

ve O

ncol

ogy

Trea

tmen

ts11

:30-

13:0

0

BREA

ST C

ANCE

R

PRO

FFER

ED P

APER

S15

:00-

16:3

0

BREA

ST C

ANCE

R

CRIT

ICAL

REV

IEW

SES

SIO

N

Criti

cal R

evie

w o

f Pre

sent

ed

Tria

ls a

nd Im

plic

atio

n in

Pr

actic

e16

:45-

18:1

5

URO

LOG

Y

MD

TU

MO

UR

BOAR

D07

:45-

08:4

5

URO

LOG

Y

CLIN

ICAL

SYM

POSI

UM

Blad

der C

ance

r10

:15-

11:1

5

CHAN

GIN

G PR

ACTI

CE

SESS

ION

Not

Eve

ry C

ance

r Cen

tre

Shou

ld T

reat

Eve

ry

Canc

er P

atie

nt. W

hat's

th

e Ev

iden

ce?

11:3

0-12

:45

SATE

LLIT

E SY

MPO

SIA

COLO

RECT

AL C

ANCE

R

PRO

FFER

ED P

APER

S15

:00-

16:3

0

COLO

RECT

AL C

ANCE

R

CRIT

ICAL

REV

IEW

SES

SIO

NCr

itic

al R

evie

w o

f Pr

esen

ted

Tria

ls a

nd

Impl

icat

ion

in P

ract

ice

16:4

5-18

:15

SATE

LLIT

E SY

MPO

SIA

GYN

AECO

LOG

Y

MD

TU

MO

UR

BOAR

D07

:45-

08:4

5

EDU

CATI

ON

ALIM

MER

SIO

N

PRO

GRAM

ME

Intr

oduc

tion

to

Imm

unot

hera

py a

nd

the

Scie

nce

Behi

nd it

(N

ovic

e)

11:1

5-12

:45

SATE

LLIT

E SY

MPO

SIA

EDU

CATI

ON

AL IM

MER

SIO

N

PRO

GRAM

ME

Adva

nced

Cou

rse

in

Imm

unol

ogy

and

Imm

unot

hera

py

(Adv

ance

d)15

:00-

17:3

0

SATE

LLIT

E SY

MPO

SIA

UPP

ER G

I - H

EPAT

OBI

LLAR

Y

MD

TU

MO

UR

BOAR

D07

:45-

08:4

5

UPP

ER G

I CAN

CER

CLIN

ICAL

SYM

POSI

UM

Tria

ls &

Out

com

e Re

sear

ch

that

Cha

nge

Prac

tice

10:1

5-11

:15

EDU

CATI

ON

AL S

ESSI

ON

Pati

ent R

epor

ted

Out

com

es11

:30-

13:0

0

CHAN

GIN

G PR

ACTI

CE

SESS

ION

Va

lue

in O

ncol

ogy

Care

13:1

5-14

:30

MEL

ANO

MA

PRO

FFER

ED P

APER

S15

:00-

16:3

0

MEL

ANO

MA

CRIT

ICAL

REV

IEW

SES

SIO

NCr

itic

al R

evie

w o

f Pr

esen

ted

Tria

ls a

nd

Impl

icat

ion

in P

ract

ice

16:4

5-18

:15

SATE

LLIT

E SY

MPO

SIA

PATI

ENT

ADVO

CACY

SE

SSIO

N

Side

Effe

cts:

Out

of

Sigh

t Out

of M

ind

10:1

5-11

:15

SATE

LLIT

E SY

MPO

SIA

PATI

ENT

ADVO

CACY

SE

SSIO

N

Tran

slat

ing

Rese

arch

into

Pa

tient

Val

ue15

:00-

16:3

0

PATI

ENT

ADVO

CACY

SE

SSIO

N

Cont

rove

rsie

s in

Care

- M

yths

and

Rea

litie

s16

:45-

18:1

5

SATE

LLIT

E SY

MPO

SIA

POST

ERS

POST

ER V

IEW

ING

(12:

00-1

4:00

)

POST

ERS

POST

ER V

IEW

ING

(16:

00-1

8:00

)

IND

UST

RY S

POTL

IGH

T SE

SSIO

NS

(09:

30-1

0:30

)

IND

UST

RY S

POTL

IGH

T SE

SSIO

NS

(11:

00-1

2:00

)

IND

UST

RY S

POTL

IGH

T SE

SSIO

NS

(13:

30-1

4:30

)

IND

UST

RY S

POTL

IGH

T SE

SSIO

NS

(16:

30-1

7:30

)

IND

UST

RY S

POTL

IGH

T SE

SSIO

NS

(15:

00-1

6:00

)

EDU

CATI

ON

AL S

ESSI

ON

Acqu

irin

g Pr

acti

cal S

kills

: D

esig

ning

Pro

ject

s,

Effe

ctiv

enes

s in

Wri

ting

, Fu

ndin

g Yo

ur R

esea

rch

and

Spea

king

10:1

5-12

:15

SATE

LLIT

E SY

MPO

SIA

EDU

CATI

ON

AL S

ESSI

ON

How

to E

ffici

entl

y ru

n a

Tum

our B

oard

(rep

eate

d)07

:45-

08:4

5

EDU

CATI

ON

AL S

ESSI

ON

Can

we

Affo

rd it

? H

ow to

Det

erm

ine

Cost

Ef

fect

iven

ess (

Repe

ated

)10

:15-

11:4

5

SATE

LLIT

E SY

MPO

SIA

PALL

IATI

VE A

ND

SU

PPO

RTIV

E CA

RE

PRO

FFER

ED P

APER

S15

:00-

16:3

0

PALL

IATI

VE A

ND

SU

PPO

RTIV

E CA

RE

CRIT

ICAL

REV

IEW

SES

SIO

NCr

itic

al R

evie

w o

f Pr

esen

ted

Tria

ls a

nd

Impl

icat

ion

in P

ract

ice

16:4

5-18

:15

SATE

LLIT

E SY

MPO

SIA

LUN

CH

12:4

5 - 1

4:45

HEA

D &

NEC

K CA

NCE

R

MD

TU

MO

UR

BOAR

D07

:45-

08:4

5

HEA

D &

NEC

K CA

NCE

R

CLIN

ICAL

SYM

POSI

UM

Tria

ls &

Out

com

e Re

sear

ch

that

Cha

nge

Prac

tice

10:1

5-11

:15

EDU

CATI

ON

AL S

ESSI

ON

Canc

er Im

agin

g: A

Key

Co

mpo

nent

of

Pers

onal

ised

Onc

olog

y 11

:30-

13:0

0

CHAN

GIN

G PR

ACTI

CE

SESS

ION

Yes,

Dat

a Ca

n Ta

lk

Toge

ther

13.1

5-14

:45

HEA

D &

NEC

K CA

NCE

R

PRO

FFER

ED P

APER

S15

:00-

16:3

0

HEA

D &

NEC

K CA

NCE

R

CRIT

ICAL

REV

IEW

SES

SIO

NCr

itic

al R

evie

w o

f Pr

esen

ted

Tria

ls a

nd

Impl

icat

ion

in P

ract

ice

16:4

5-18

:15

SATE

LLIT

E SY

MPO

SIA

EDU

CATI

ON

AL S

ESSI

ON

How

to e

ffici

entl

y ru

na

Tum

our B

oard

07:4

5-08

:45

CE

NTR

AL N

ERVO

US

SYST

EM

CLIN

ICAL

SYM

POSI

UM

Brai

n M

etas

tase

s10

:15-

11:1

5

EMA

AND

HTA

S

REGU

LATO

RY S

ESSI

ON

EMA

and

HTA

s on

the

Hot

Sea

t11

:30-

12:4

5

SATE

LLIT

E SY

MPO

SIA

CLIN

ICAL

SYM

POSI

UM

CNS/

CHIL

DH

OO

DCA

NCE

RS

15:0

0-16

:00

REG

ULA

TORY

SES

SIO

N

Case

Stu

dies

in

Appr

oval

s of

Tar

gete

d Ag

ents

: Sin

gle-

Arm

Tri

als

16:1

0 - 1

7:10

REG

ULA

TORY

SES

SIO

N

Real

-life

Impl

emen

tati

on

of B

iom

arke

r Inf

orm

atio

n to

Info

rm T

reat

men

t and

Re

gula

tory

Dec

isio

ns -

the

PD-L

1 Ex

peri

ence

17:1

5-18

:15

CEN

TRAL

NER

VOU

SSY

STEM

MD

TU

MO

UR

BOAR

D07

:45-

08:4

5

EDU

CATI

ON

ALIM

MER

SIO

N

PRO

GRAM

ME

Intr

oduc

tion

to O

mic

san

d Pe

rson

alis

ed

Med

icin

e (N

ovic

e)10

:15-

11:4

5

POLI

CY S

ESSI

ON

I

How

can

Onc

opol

icy

Stre

ngth

en

Mul

tidi

scip

linar

y Pr

acti

ce?

13:1

5-14

:45

EDU

CATI

ON

AL

IMM

ERSI

ON

PR

OGR

AMM

E

Pers

onal

ised

M

edic

ine:

Fro

m

Gen

omic

s to

Clin

ical

Pr

acti

ce (A

dvan

ced)

15:4

5-18

:15

SATE

LLIT

E SY

MPO

SIA

BREA

ST C

ANCE

R I

MD

TU

MO

UR

BOAR

D07

:45-

08:4

5

PLEN

ARY

SESS

ION

PRAC

TICE

CH

ANGI

NG

TRIA

LS I

09:0

0-10

:00

BREA

ST C

ANCE

R

CLIN

ICAL

SYM

POSI

UM

Tria

ls &

Out

com

e Re

sear

ch

that

Cha

nge

Prac

tice

10:1

5-11

:15

EDU

CATI

ON

AL S

ESSI

ON

Real

Wor

ld D

ata:

H

ealt

h O

utco

mes

Re

sear

ch11

:30-

13:0

0

THO

RACI

C CA

NCE

R

PRO

FFER

ED P

APER

S15

:00-

16:3

0

HO

T D

EBAT

E

TOPI

C TB

A

16:4

5-17

:45

RECT

AL C

ANCE

R

MD

TU

MO

UR

BOAR

D07

:45-

08:4

5

COLO

RECT

AL C

ANCE

R

CLIN

ICAL

SYM

POSI

UM

Tria

ls &

Out

com

e Re

sear

ch

that

Cha

nge

Prac

tice

10:1

5-11

:15

CHAN

GIN

G PR

ACTI

CE

SESS

ION

Affo

rdab

ility

of

Inno

vati

on in

Can

cer

Care

: How

to B

end

the

Cost

Cur

ve in

an

Era

of

Tech

nolo

gy E

volu

tion

11:3

0-12

:45

SATE

LLIT

E SY

MPO

SIA

URO

LOG

Y

PRO

FFER

ED P

APER

S15

:00-

16:3

0

EDU

CATI

ON

AL S

ESSI

ON

Tom

orro

w's

Clin

ical

/ Pr

acti

cal A

pplic

atio

ns

of L

iqui

d Bi

opsy

16:4

5-18

15

SATE

LLIT

E SY

MPO

SIA

MEL

ANO

MA

CLIN

ICAL

SYM

POSI

UM

Tria

ls &

Out

com

e Re

sear

ch

that

Cha

nge

Prac

tice

10:1

5-11

:15

JOIN

T EC

CO-J

SCO

SESS

ION

TOPI

C TB

A11

:30-

12:4

5

SATE

LLIT

E SY

MPO

SIA

ECCO

SES

SIO

N

Qua

lity

Canc

er C

are

Indi

cato

rs

15:0

0-16

:30

GYN

AECO

LOGI

CAL C

ANCE

R -

EARL

Y CE

RVIC

AL C

ANCE

R

CLIN

ICAL

SYM

POSI

UM

Inno

vati

ve S

urge

ry V

ersu

s In

nova

tive

Rad

ioth

erap

y16

:45-

18:1

5

SATE

LLIT

E SY

MPO

SIA

PALL

IATI

VE

& S

UPP

ORT

IVE

CARE

MD

TU

MO

UR

BOAR

DEn

d of

life

07:4

5-08

:45

EDU

CATI

ON

AL S

ESSI

ON

Can

we

Affo

rd it

? H

ow to

Det

erm

ine

Cost

Eff

ecti

vene

ss10

:15-

11:4

5

SATE

LLIT

E SY

MPO

SIA

EDU

CATI

ON

AL S

ESSI

ON

Evid

ence

-bas

edM

anag

emen

t of C

ance

rin

Old

er P

atie

nts

16:1

5-18

:15

SATE

LLIT

E SY

MPO

SIA

POST

ERS

POST

ER V

IEW

ING

(12:

00-1

4:00

)

POST

ERS

POST

ER V

IEW

ING

(16:

00-1

8:00

)

IND

UST

RY S

POTL

IGH

T SE

SSIO

NS

(09:

30-1

0:30

)

IND

UST

RY S

POTL

IGH

T SE

SSIO

NS

(11:

00-1

2:00

)

IND

UST

RY S

POTL

IGH

T SE

SSIO

NS

(13:

30-1

4:30

)

IND

UST

RY S

POTL

IGH

T SE

SSIO

NS

(16:

30-1

7:30

)

IND

UST

RY S

POTL

IGH

T SE

SSIO

NS

(15:

00-1

6:00

)

LYM

PHO

MA

MD

TU

MO

UR

BOAR

D07

:45-

08:4

5

PRI

MAR

Y CA

RE S

ESSI

ON

The

Expa

ndin

g Ro

le

of P

rim

ary

Care

in

Canc

er M

anag

emen

t10

:15-

11:1

5

PRIM

ARY

CARE

SES

SIO

N

Dia

gnos

ing

Canc

er

Earl

y - T

he M

ost E

ffec

tive

St

rate

gy to

Impr

ove

Surv

ival

: Cur

rent

Issu

es in

Sc

reen

ing

and

Dia

gnos

is11

:30-

12:4

5

SATE

LLIT

E SY

MPO

SIA

PRIM

ARY

CARE

SES

SIO

N

Trea

tmen

t and

M

anag

emen

t of C

ance

r Pa

tien

ts &

Sur

vivo

rs :

the

need

for j

oine

d-up

ap

proa

ches

15:0

0-16

:30

PRIM

ARY

CARE

SES

SIO

N

Inte

grat

ed M

odel

s of

Ca

ncer

Man

agem

ent:

Brin

ging

Pri

mar

y Ca

re a

nd

Seco

ndar

y Ca

re T

oget

her

16:4

5-18

:15

SATE

LLIT

E SY

MPO

SIA

CHIL

DH

OO

D C

ANCE

RS I

MD

TU

MO

UR

BOAR

D07

:45-

08:4

5

NEU

ROEN

DO

CRIN

E TU

MO

URS

CLIN

ICAL

SYM

POSI

UM

10:1

5-11

:15

EDU

CATI

ON

AL S

ESSI

ON

Reco

gnis

ing

and

Man

agin

g Et

hica

l Ch

alle

nges

in

Canc

er C

are

11:3

0-13

:00

SATE

LLIT

E SY

MPO

SIA

RARE

CAN

CERS

-

SARC

OM

AS

PRO

FFER

ED P

APER

S15

:00-

16:3

0

RARE

CAN

CERS

-

SARC

OM

AS

CLIN

ICAL

SYM

POSI

UM

16:4

5-18

:15

SATE

LLIT

E SY

MPO

SIA

LUN

CH

12:4

5 - 1

4:45

LUN

CH

12:4

5 - 1

4:45

14 15ECCO2017 - From Evidence to Practice in Multidisciplinary Cancer Care - Advance Programme eccocongress.org

MULTIDISCIPLINARY TUMOUR BOARD SESSION

Case presentation discussed by a multidisciplinary board, with interaction of the audience. An expert moderator leads the session presenting common cases.

PLENARY SESSION

Presentations of the new and late breaking practice changing data representing the four pillars of the programme.

CLINICAL SYMPOSIUM

Presentations of key practice changing trials and real world data, it can be new data or presented in the last 12 months (which will be updated, if applicable).

CHANGING PRACTICE SESSION

These sessions discuss the organisation of cancer services for the future, the health economics of cancer treatment and methodologies for outcome research.

PROFFERED PAPER SESSION

Oral presentations of the best and new late breaking abstracts and optionally also including invited speaker abstracts on key practice changing data and outcome research.

POSTER SESSION

Presentations in poster format of selected abstracts based on the four pillars of the programme.

ECCO2017 SESSION TYPES

CRITICAL REVIEW SESSION

Critical review of the trials presented in the plenary session, clinical symposia and proffered papers. Experts from different disciplines will give an overview of the implications for practice. In addition, one top expert will question and define the value of these new treatments in a multidisciplinary context. The session will host a roundtable discussion with a panel and audience; ending with interaction with the audience on whether they agree with the panel.

PATIENT ADVOCATE PROGRAMME

Sessions discussing topics that influence cancer care. These sessions are open to all delegates.

EDUCATIONAL IMMERSION PROGRAMME – NOVICE LEVEL/ADVANCED LEVEL

This course is aimed at audiences with either novel or advanced knowledge, giving in-depth education on two hot topics. Participants can also follow both basic and advanced level sessions to get high immersion into the topic.

EDUCATIONAL SESSION

State of the art lectures on topics that impact on daily practice and giving knowledge on health economics and outcome research.

POLICY SESSION

Presenting and discussing ECCO activities related to policy.

PRIMARY CARE PROGRAMME

Programme devised for primary care physicians and the oncology community to discuss topics related to primary care involvement in cancer care.

PR

OG

RA

MM

E O

VE

RV

IEW

UPP

ER G

I

MD

TU

MO

UR

BOAR

DO

esop

hage

al C

ance

r 07

:45-

08:4

5

CHAN

GIN

G PR

ACTI

CESE

SSIO

N

Equi

ty in

Can

cer C

are:

St

ill a

Lon

g W

ay to

Go

09:0

0-10

:00

EDU

CATI

ON

AL S

ESSI

ON

Evid

ence

-Bas

ed P

ublic

H

ealt

h In

terv

enti

ons

to

Prev

ent C

ance

r10

:15-

11:4

5

SATE

LLIT

E SY

MPO

SIA

REGU

LATO

RY S

ESSI

ON

Regu

lati

ng In

nova

tion

in

Loca

l Reg

iona

l Tre

atm

ent

09:0

0-11

:00

TIM

E FO

R

SATE

LLIT

E SY

MPO

SIA

EDU

CATI

ON

AL S

ESSI

ON

Inef

ficie

ncie

s in

Can

cer

Care

09:0

0-10

:30

BREA

ST C

ANCE

R II

MD

TU

MO

UR

BOAR

D07

:45-

08:4

5

CLIN

ICAL

SYM

POSI

UM

G

ENER

AL

Man

agin

gO

ligom

etas

tati

cD

isea

se09

:00-

10:0

0

THO

RACI

C CA

NCE

R

CRIT

ICAL

REV

IEW

SES

SIO

N

Crit

ical

Rev

iew

of

Pres

ente

d Tr

ials

and

Im

plic

atio

n in

Pra

ctic

e10

:15-

11:4

5

PLEN

ARY

SESS

ION

Prac

tice

Cha

ngin

g Tr

ials

III

12:0

0-13

:00

COLO

N C

ANCE

R

MD

TU

MO

UR

BOAR

D07

:45-

08:4

5

CHAN

GIN

G PR

ACTI

CESE

SSIO

N

Lung

Can

cer

Scre

enin

g: C

an W

eAf

ford

Not

to?

09:0

0-10

:00

URO

LOG

Y

CRIT

ICAL

REV

IEW

SES

SIO

NCr

itic

al R

evie

w o

f Pr

esen

ted

Tria

ls a

nd

Impl

icat

ion

in P

ract

ice

10:1

5-11

:45

RESE

RVED

TIM

E

SATE

LLIT

E SY

MPO

SIA

EDU

CATI

ON

AL S

ESSI

ON

Reco

gnis

ing

and

Avoi

ding

Bia

s in

Cl

inic

al T

rial

s08

:30-

10:0

0

CHAN

GIN

G PR

ACTI

CE

SESS

ION

Exte

rnal

Val

idit

y of

Cl

inic

al T

rial

s10

:15-

11:1

5

SATE

LLIT

E SY

MPO

SIA

OLI

GIO

MET

ASTA

TIC

DIS

EASE

MD

TU

MO

UR

BOAR

D07

:45-

08:4

5

PRO

FFER

ED P

APER

S

Upp

er G

I Can

cer

09:0

0-10

:15

UPP

ER G

I

CRIT

ICAL

REV

IEW

SES

SIO

NCr

itic

al R

evie

w o

f Pr

esen

ted

Tria

ls a

nd

Impl

icat

ion

in P

ract

ice

10:3

0-11

:45

CHIL

DH

OO

D C

ANCE

RS II

MD

TU

MO

UR

BOAR

D07

:45-

08:4

5

EDU

CATI

ON

AL S

ESSI

ON

Prac

tici

ng O

ncol

ogy

in

Coun

trie

s w

ith

Lim

ited

Re

sour

ces

09:0

0-10

:30

SATE

LLIT

ES

SATE

LLIT

E SY

MPO

SIA

Post

ers

POST

ER V

IEW

ING

(12:

30-1

4:30

)

PALL

IATI

VE A

ND

SU

PPO

RTIV

E CA

RE

MD

TU

MO

UR

BOAR

DPa

lliat

ive

and

Supp

orti

ve

Care

- El

derl

y07

:45-

08:4

5

WO

RKSH

OP

The

Art o

f Des

igni

ng

Clin

ical

Tri

als:

The

Lat

est i

n M

etho

ds in

Clin

ical

Canc

er R

esea

rch

09:0

0-12

:00 RE

SERV

ED

SATE

LLIT

E SY

MPO

SIA

CLIN

ICAL

TRI

ALS

INVE

STIG

ATO

R'S

MEE

TIN

GS

Bre

ast

CN

S E

duca

tion

al L

ymph

oma

Neu

roen

docr

ine

Pri

mar

y Ca

re S

arco

mas

Cha

ngin

g Pr

acti

ce S

essi

on C

olor

ecta

l G

ynae

colo

gy I

ndus

try

Spot

light

ses

sion

s P

allia

tive

Car

e P

oste

r vie

win

g T

hora

cic

Chi

ldho

od C

ance

rs

ECC

O S

essi

on H

ead

and

Nec

k M

elan

oma

Ple

nary

Ses

sion

Sat

ellit

e Sy

mpo

sia

Uro

logy

Upp

er G

I H

aem

atol

ogy

IND

UST

RY S

POTL

IGH

T SE

SSIO

NS

(09:

30-1

0:30

)

IND

UST

RY S

POTL

IGH

T SE

SSIO

NS

(13:

30-1

4:30

)

IND

UST

RY S

POTL

IGH

T SE

SSIO

NS

(15:

00-1

6:00

)

IND

UST

RY S

POTL

IGH

T SE

SSIO

NS

MO

ND

AY

30

TH J

AN

UA

RY

20

17

Rare

Can

cers


GENERAL SESSIONSGENERAL SESSIONS

SATURDAY 28 JANUARY 2017

09:00 - 10:00

Plenary Session: Practice Changing Trials I Best and late-breaking oral abstracts to be announced in the online searchable programme as soon as possible

11:30 - 12:45

Joint Session: ECCO-JSCO Joint Session

Details to be announced in the online searchable programme as soon as possible

15:00 - 16:30

ECCO Session: Quality Cancer Care Indicators


SUNDAY 29 JANUARY 2017

09:00 - 10:00

Plenary Session: Practice Changing Trials II

Best and late-breaking oral abstracts to be announced in the online searchable programme as soon as possible

11:30 - 12:45

Joint Session: Joint ECCO-ASCO Session


MONDAY 30 JANUARY 2017

07:45 - 08:45

Multidisciplinary Tumour Board: Oligometastatic Disease

Case presentation

Moderator: M. Guckenberger (Switzerland)

GI Surgeon Panel: P. Piso (Germany)

Radiation oncologist Panel: J. Widder (Netherlands)

Thoracic surgeon Panel: I. Schmitt-Opitz (Switzerland)

Radiologist To be announced

Medical oncologist Panel: C.J.A. Punt (Netherlands)

Nuclear medicine physician Panel: A. Chiti (Italy)

Oncology nurse To be announced

09:00 - 10:00

Clinical Symposium: Managing Oligometastatic Disease Chair: M. Guckenberger (Switzerland)

Chair: T. Gruenberger (Austria)

Peri-operative chemotherapy in patients with resectable colorectal liver metastases - lessons learned from the New EPOC trial Speaker: J. Primrose (United Kingdom)

Salvage treatment or active clinical surveillance for oligometastatic prostate cancer: A randomised Phase II Trial Speaker: G. De Meerleer (Belgium)

Stereotactic ablative radiotherapy for oligometastatic non-small cell lung cancer: A randomised Phase III Trial Speaker: D. Landau (United Kingdom)

Phase I clinical study combining L19-IL2 with stereotactic ablative body radiotherapy in patients with oligometastatic solid tumour Speaker: P. Lambin (Netherlands)

GENERAL SESSIONS

09:00 - 12:00

Workshop: The Art of Designing Clinical Trials: The Latest in Methods in Clinical Cancer Research

Chair: S. Sleijfer (Netherlands)

Chair: L. De Mattos-Arruda (Spain)

Introductory remarks Speaker: L. De Mattos-Arruda (Spain)

ECCO-AACR-EORTC-ESMO Workshop on Methods in Clinical Cancer Research: A platform to learn the essentials of good clinical trial design Speaker: S. Sleijfer (Netherlands)

Challenges faced by young oncologists executing clinical trials

The Flims Alumni Club Speaker: L. De Mattos-Arruda (Spain)

Surgical oncologist’s perspective Speaker: J.R. Van der Vorst (Netherlands)

Medical oncologist’s perspective Speaker: B. Sousa (Portugal)

Designing a clinical trial to improve cancer medicine: Questions you must ask Speaker: L.L. Siu (Canada)

Expert exchange: Hot topics in cancer clinical trials Genotype-based clinical trials Speaker: J.C. Soria (France)

Assessing anti-tumour activity of immunotherapeutic agents Speaker: J.B.A.G. Haanen (Netherlands)

Clinically relevant differences of new oncology treatments: What to aim for? Speaker: M. Piccart (Belgium)

Expert panel: Assess and evaluate cancer clinical trial concepts Medical Oncologist Panel: S. Sleijfer (Netherlands)

Medical Oncologist Panel: L.L. Siu (Canada)

Statistician Panel: J. Bogaerts (Belgium)

Trial concept presentation 1 Speaker: To be announced

Panel discussion Trial concept presentation 2 Speaker: To be announced

Panel discussion

Trial concept presentation 3 Speaker: To be announced

Panel discussion

Concluding remarks Speaker: S. Sleijfer (Netherlands)

12:00 - 13:00

Plenary Session: Practice Changing Trials III

Best and late-breaking oral abstracts to be announced in the online searchable programme as soon as possible


GENERAL SESSIONS GENERAL SESSIONSBREAST CANCER


07.45 - 08:45 Multidisciplinary Tumour Board: Breast Cancer I

Case presentation: Management of the axilla Moderator: I.T. Rubio (Spain)

Surgical oncologist Panel: J. Van der Hage (Netherlands)

Medical oncologist Panel: P. Conte (Italy)

Radiation oncologist Panel: C.E. Coles (United Kingdom)

Imaging specialist Panel: F. Sardanelli (Italy)

Pathologist Panel: G. Cserni (Hungary)

Oncology nurse Panel: D. Van der Meer (Netherlands)

10.15 - 11:15

Clinical Symposium: Breast Cancer Trials and Outcome Research that Change Practice

Chair: B. Offersen (Denmark)

Chair: P. Conte (Italy)

MINDACT TrialSpeaker: M. Piccart (Belgium)

ESME HER 2 +ve TrialSpeaker: S. Delaloge (France)

Partial irradiation: GEC-ESTRO TrialSpeaker: V. Strnad (Germany)

Partial irradiation: Import LOW TrialSpeaker: C.E. Coles (United Kingdom)


15:00 - 16.30

Proffered Papers: Breast Cancer

Presentation of Selected Abstracts

16:45 - 18:15

Critical Review: Breast Cancer - Critical Review of Presented Trials and Implication in Practice

Chair: O. Pagani (Switzerland)

Chair: To be announced

Medical oncology perspectiveSpeaker: M. Piccart (Belgium)

Radiation oncology perspectiveSpeaker: J.R. Yarnold (United Kingdom)

Surgical oncology perspectiveSpeaker: L. Wyld (United Kingdom)

What is the value of these new treatments?Speaker: To be announced

Panel DiscussionMedical oncologistPanel: M. Piccart (Belgium)

Radiation oncologistPanel: J.R. Yarnold (United Kingdom)

Surgical oncologistPanel: L. Wyld (United Kingdom)

Oncology nursePanel: Y. Wengström (Sweden)

Patient advocatePanel: To be announced


07:45 - 08.45

Multidisciplinary Tumour Board: Breast Cancer II

Case presentation: Are there limits to breast conservation?Moderator: E.J.T. Rutgers (Netherlands)

Surgical oncologistPanel: O. Gentilini (Italy)

Medical oncologistPanel: D.A. Cameron (United Kingdom)

Radiation oncologistPanel: B. Cutuli (France)

Imaging specialistPanel: P. Steyerova (Czech Republic)

Clinical geneticistPanel: N. Hoogerbrugge (Netherlands)Oncology nursePanel: D. Fenlon (United Kingdom)

CENTRAL NERVOUS SYSTEM


07:45 - 08:45

Multidisciplinary Tumour Board: Central Nervous System

Case presentation: Low-grade glioma patientModerator: M.J.B Taphoorn (Netherlands)

NeurosurgeonPanel: To be announced

Radiation oncologistPanel: B. Baumert (Germany)

Neuro oncologistPanel: M.J. Van den Bent (Netherlands)

Paediatric oncologistPanel: To be announced

Oncology nursePanel: H. Zwinkels - van vliet (Netherlands)

10:15 - 11:15

Clinical Symposium: Central Nervous System - Brain Metastases

Chair: M. Brada (United Kingdom)

Targeted agents in brain metastasesSpeaker: To be announced

Stereotactic radiosurgerySpeaker: G. Minniti (Italy)

Hippocampal avoidance IMRTSpeaker: D.C. Weber (Switzerland)

Title: To be announcedSpeaker: To be announced

15:00 - 16:00

Clinical Symposium: CNS/Childhood Cancers

Chair: M.J. Van den Bent (Netherlands)

MedulloblastomaSpeaker: To be announced

Tumour biologySpeaker: S. Pfister (Germany)

High grade gliomaSpeaker: D. Hargrave (United Kingdom)

EpendyomaSpeaker: D. Frappaz (France)


10:15 - 11:15

Clinical Symposium: Central Nervous System - Glioma and Immunotherapy

Chair: M. Weller (Switzerland)

Chair: W. Wick (Germany)

Immunotherapy/EGFRviiiSpeaker: M. Weller (Switzerland)

EORTC 26053 CATNONSpeaker: M.J. Van den Bent (Netherlands)

EORTC 26033 Low-grade gliomaSpeaker: B. Baumert (Germany)

Tumour treating fieldsSpeaker: R. Stupp (Switzerland)

16:45 - 18:15

Critical Review: Central Nervous System - Critical Review of Presented Trials and Implication in Practice

Chair: P. Wen (USA)

Chair: K. Oliver (United Kingdom)

NeurologySpeaker: W. Wick (Germany)

RadiotherapySpeaker: M. Krause (Germany)

NeurosurgerySpeaker: To be announced

What is the value of these new treatments?Speaker: P. Wen (USA)

Panel Discussion

NeurologyPanel: W. Wick (Germany)

RadiotherapyPanel: M. Krause (Germany)

NeurosurgeryPanel: To be announced

Oncology nursingPanel: To be announced

Patient advocacyPanel: K. Oliver (United Kingdom)


GENERAL SESSIONS GENERAL SESSIONSCHILDHOOD CANCERS


07:45 - 08:45

Multidisciplinary Tumour Board: Childhood Cancers I

Case presentation: Brain tumoursModerator: To be announced

Paediatric oncologistPanel: F. Doz (France)

Radiation oncologistPanel: T. Boterberg (Belgium)

Paediatric oncologistPanel: R. Riccardi (Italy)

Paediatric oncologistPanel: L.J. Hjorth (Sweden) Adult oncologistPanel: D. Frappaz (France) Oncology NursePanel: To be announced


15:00 - 16:30

Clinical Symposium: Childhood Cancers - Translational Approaches in Paediatric Oncology

Chair: M. Schrappe (Germany)

Chair: G. Vassal (France)

Introduction - Translation from pathway to clinical practice Speaker: P. Kearns (United Kingdom)

Therapeutic translation of novel biological findings in neuroblastoma Speaker: R. Ladenstein (Austria)

Introduction of novel classes of therapeutics in haematological malignancies Speaker: A. Von Stackelberg (Germany)

Integrated approaches in malignant lymphoma Speaker: C. Patte (France)

Liver tumours: Novel clinical research through transfer of expert advice in an European effort Speaker: B.J. Morland (United Kingdom)

Discussion

16:45 - 18:15

Critical Review: Childhood Cancers - Sarcomas - Critical Review of Presented Trials and Implication in Practice

Chair: S. Bielack (Germany)

IntroductionSpeaker: L. Brugieres (France)

Medical oncology approaches to paediatric type sarcomasSpeaker: To be announced

Paediatric oncology approaches to adult type sarcomasSpeaker: A. Ferrari (Italy)

Paediatric surgerySpeaker: To be announced

Proton therapySpeaker: M. Krause (Germany)

What is the value of these new treatments?Speaker: B.J. Morland (United Kingdom)

Medical oncologistPanel: To be announced

Paediatric oncologistPanel: A. Ferrari (Italy)

Paediatric surgeonPanel: To be announced

Radiation oncologistPanel: M. Krause (Germany)


07:45 - 08:45

Childhood Cancers

Multidisciplinary Tumour Board: Childhood Cancers II

Case presentation: Leukaemia Moderator: M. Schrappe (Germany)

Paediatric oncologistPanel: J. Stary (Czech Republic)

Paediatric oncologistPanel: A. Biondi (Italy)

Adult oncologistPanel: To be announced

ImmunologistPanel: To be announced

Oncology NursePanel: C. Freidank (Germany)

COLORECTAL CANCER


07:45 - 08:45

Multidisciplinary Tumour Board: Rectal Cancer

Case presentationModerator: V. Valentini (Italy)

Surgical oncologistPanel: E. Angenete (Sweden)

Medical oncologistPanel: C.J.A. Punt (Netherlands)

Radiation oncologistPanel: C. Rödel (Germany)

Imaging specialistPanel: R.G.H. Beets-Tan (Netherlands)

PathologistPanel: P. Quirke (United Kingdom)

Oncology nursePanel: C. Taylor (United Kingdom)

10:15 - 11:15

Clinical Symposium: Colorectal Cancer - Trials and Outcome Research that Change Practice

Chair: C.J.A. Punt (Netherlands)

Chair: K. Haustermans (Belgium)

PRODIGE 7 TrialSpeaker: F. Quenet (France)

FOXTROT TrialSpeaker: D. Morton (United Kingdom)

Rapido TrialSpeaker: C. Marijnen (Netherlands)

5x5 plus chemo TrialSpeaker: K. Bujko (Poland)


15:00 - 16:30

Proffered Papers: Colorectal CancerPresentation of Selected Abstracts

16:45 - 18:15

Critical Review: Colorectal Cancer - Critical Review of Presented Trials and Implication in Practice

Chair: C.J.H. Van de Velde (Netherlands)

Chair: J. Gore-Booth (France)

Medical oncology perspective Speaker: To be announced

Radiation oncology perspective Speaker: D. Sebag-Montefiore (United Kingdom)

Surgical oncology perspective Speaker: C. Coco (Italy)

What is the value of these new treatments? Speaker: C. Marijnen (Netherlands)

Panel Discussion

Medical oncologist Panel: C. Earl (Canada)

Radiation oncologist Panel: D. Sebag-Montefiore (United Kingdom)

Surgical oncologist Panel: C. Coco (Italy)

Pathologist Panel: To be announced

Oncology nurse Panel: To be announced

Patient advocate Panel: J. Gore-Booth (France)


07:45 - 08:45

Multidisciplinary Tumour Board: Colon Cancer

Case presentation Moderator: E. Angenete (Sweden)

Surgical oncologist Panel: G. Poston (United Kingdom)

Medical oncologist Panel: C.J.A. Punt (Netherlands)

Radiation oncologist Panel: V. Valentini (Italy)

Imaging specialist Panel: R.G.H. Beets-Tan (Netherlands)

Pathologist Panel: To be announced

Oncology nurse Panel: C. Taylor (United Kingdom)


GENERAL SESSIONS GENERAL SESSIONSGYNAECOLOGICAL CANCER


16:45 - 18:15

Clinical Symposium: Gynaecological Cancer - Early Cervical Cancer: Innovative Surgery Versus Innovative Radiotherapy



Image Guided Brachytherapy in Locally Advanced Cervical Cancer: improved pelvic control and survival in RetroEMBRACE, a multi-centred cohort study Speaker: R. Pötter (Austria)

Total mesometrial resection (TMMR) in cervical cancer with therapeutic lymph-adenectomy and avoidance of adjuvant radiotherapy translated to robotic surgery Speaker: P. Wimberger (Germany)

Pivotal Trial: PARP-inhibitor maintenance therapy in patients with BRCA mutation and platinum-sensitive serous ovarian cancer relapse Speaker: To be announced

Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial Speaker: M. Gore (United Kingdom)

Discussion


07:45 - 08:45

Multidisciplinary Tumour Board: Gynaecology

Case Presentation:

1: High-risk endometrial cancer 2: Uterus sarcoma after morcellementModerator: P. Wimberger (Germany)

Medical oncologistPanel: M. Gore (United Kingdom)

Radiation oncologistPanel: R. Nout (Netherlands)

Imaging specialistPanel: V. Vandecaveye (Belgium)

PathologistPanel: W.G. McCluggage (United Kingdom)

GynaecologistPanel: H. Nijman (Netherlands)

Oncology nursePanel: To be announced

HAEMATOLOGY


07:45 - 08:45

Multidisciplinary Tumour Board: Lymphoma

Case presentationModerator: F. Cavalli (Switzerland)

HaematologistPanel: M. Ladetto (Italy)

PathologistPanel: To be announced

Radiation oncologistPanel: L. Specht (Denmark)

Nuclear medicine physicianPanel: F. Bodere (France)

Oncology nursePanel: J. De Munter (Belgium)


16:45 - 18:15

Critical Review: Haematology - Critical Review of Presented Trials and Implication in Practice

Chair: E. Kimby (Sweden)

Chair: S. Diler (Turkey)

Chemotherapy free in follicular lymphoma

Speaker: E. Kimby (Sweden)

What’s new in multiple myeloma?

Speaker: To be announced

PET-guided treatment of HL

Speaker: M. Hutchings (Denmark)

Biological determinants in the treatment of CLL

Speaker: D. Rossi (Switzerland)

What is the value of these new treatments? Speaker: To be announced

Panel Discussion

Haematologist Panel: E. Kimby (Sweden)

Haematologist Panel: To be announced

Nuclear medicine physician Panel: M. Hutchings (Denmark)

Haematologist Panel: D. Rossi (Switzerland)

Paediatric oncologist Panel: M. Schrappe (Germany)

Patient Advocate - Myeloma Panel: S. Diler (Turkey)


GENERAL SESSIONS GENERAL SESSIONSHEAD AND NECK CANCER


07:45 - 08:45

Multidisciplinary Tumour Board: Head and Neck

Case presentationModerator: V. Gregoire (Belgium)

Surgical oncologistPanel: C.R. Leemans (Netherlands)

Medical oncologistPanel: J. Machiels (Belgium)

Radiation oncologistPanel: H. Langendijk (Netherlands)

Imaging specialistPanel: To be announced

PathologistPanel: K. Hunter (United Kingdom)


10:15 - 11:15

Clinical Symposium: Head and Neck Cancer - Trials and Outcome Research that Change Practice

Chair: L.E. Smeele (Netherlands)


Meta-analysis on the role of induction chemotherapy in locally advanced H&N SCCSpeaker: W. Budach (Germany)

Role of induction chemotherapy in the management of nasopharyngeal carcinomaSpeaker: D. Kwong (China)

Role of immune blocker in metastatic and recurrent HNSCCSpeaker: L.L. Siu (Canada)

Molecular stratification of head and neckSpeaker: M. Baumann (Germany)

15:00 - 16:30

Proffered Papers: Head and Neck CancerPresentation of Selected Abstracts

16:45 - 18:15

Critical Review: Head & Neck Cancer - Critical Review of Presented Trials and Implication in Practice

Chair: C. Grau (Denmark)

Chair: H. Korn (Germany)

Medical oncology perspectiveSpeaker: L. Licitra (Italy)

Radiation oncology perspectiveSpeaker: V. Gregoire (Belgium)

Surgical oncology perspectiveSpeaker: J.L. Lefebvre (France)

What is the value of these new treatments?Speaker: C. Grau (Denmark)

Panel discussion

Medical oncologistPanel: L. Licitra (Italy)

Radiation oncologistPanel: V. Gregoire (Belgium)

Surgical oncologistPanel: J.L. Lefebvre (France)

Oncology nursePanel: M. Wells (United Kingdom)

Patient advocatePanel: H. Korn (Germany)

MELANOMA


10:15 - 11:15

Clinical Symposium: Melanoma - Trials and Outcome Research that Change Practice


Chair: J.B.A.G. Haanen (Netherlands)

Reductor Trial Phase II neoadjuvant anit BRAF, anti MEK treatment in primary inoperable stage III melanomaSpeaker: J.B.A.G. Haanen (Netherlands)

Checkpoint blockade and radiation therapy for brain metastasesSpeaker: To be announced

Title to be announcedSpeaker: To be announced

Ipi adjuvant trial (EORTC 18071) Speaker: A.M.M. Eggermont (France)


15:00 - 16:30

Proffered Papers: MelanomaPresentation of Selected Abstracts

16:45 - 18:15

Critical Review: Melanoma - Critical Review of Presented Trials and Implication in Practice Chair: D. Schadendorf (Germany)

Chair: G. Spurrier-Bernard (France)

Medical oncology perspectiveSpeaker: P.A. Ascierto (Italy)

Surgical oncology perspectiveSpeaker: A. Van Akkooi (Netherlands)

Radiation oncology perspectiveSpeaker: To be announced

What is the value of these new treatments?Speaker: D. Schadendorf (Germany)

Panel discussion

Medical oncologistPanel: P.A. Ascierto (Italy)

Surgical oncologistPanel: A. Van Akkooi (Netherlands)

Radiation oncologistPanel: To be announced


Patient advocacyPanel: G. Spurrier-Bernard (France)


GENERAL SESSIONS GENERAL SESSIONSPALLIATIVE AND SUPPORTIVE CARE


07:45 - 08:45

Multidisciplinary Tumour Board: Palliative and Supportive Care - End of Life

Moderator: T. Saarto (Finland)

Case Presentation: Advanced Pancreatic Cancer Speaker: F. Strasser (Switzerland)

Case Presentation: GBM in young person with dependents Speaker: P. Hoskin (United Kingdom)

Case Presentation: Advanced Prostate Cancer Speaker: A. Charalambous (Cyprus)

Radiation oncologistPanel: P. Hoskin (United Kingdom)

Palliative care specialistPanel: T. Saarto (Finland)

Medical oncologistPanel: F. Strasser (Switzerland)

Medical oncologist - painPanel: N.I. Cherny (Israel)

Oncology nursePanel: A. Charalambous (Cyprus)

Oncology nursePanel: H. Ullgren (Sweden)


10:15 - 11:15

Clinical Symposium: Palliative and Supportive Care - Trials and Outcome Research that Change Practice

Chair: P. Hoskin (United Kingdom)

Chair: H. Wildiers (Belgium)

IAEA randomised trial of optimal single dose radiotherapy in the treatment of painful bone metastasesSpeaker: P. Hoskin (United Kingdom)

Single-fraction versus 5-fraction radiation therapy for metastatic epidural spinal cord compression in patients with limited survival prognoses: Results of a matched-pair analysisSpeaker: D. Rades (Germany)

Early palliative care for patients with advanced cancer: A cluster-randomised controlled trialSpeaker: C. Zimmermann (Canada)

Discussing prognosis and end-of-life care in the final year of life: A randomised controlled trial of a nurse-led communication support programme for patients and caregiversSpeaker: A. Walczak (Australia)

How to introduce Voicing My CHOiCES (TM), an advance care planning guide for adolescents and young adultsSpeaker: To be announced

Discussion

PALLIATIVE AND SUPPORTIVE CARE

15:00 - 16:30

Proffered Papers: Palliative and Supportive Care Presentation of Selected Abstracts

16:45 - 18:15

Critical Review: Palliative and Supportive Care - Critical Review of Presented Trials and Implication in Practice

Chair: S. Kaasa (Norway)

Chair: N. Philippou (Cyprus)

Palliative careSpeaker: I. Higginson (United Kingdom)

Palliative care specialistSpeaker: M. Bakitas (USA)

Psychological aspectsSpeaker: G. Grande (United Kingdom)

What is the value of these new treatments?Speaker: P. Larkin (Ireland)

Panel Discussion

Palliative carePanel: I. Higginson (United Kingdom)

AnaesthesiologyPanel: M. Bakitas (USA)

Psychological aspectsPanel: G. Grande (United Kingdom)

Patient advocatePanel: N. Philippou (Cyprus)


07:45 - 08:45

Multidisciplinary Tumour Board: Palliative and Supportive Care - Elderly

Moderator: H. Wildiers (Belgium)

Case Presentation: Breast CancerSpeaker: H. Wildiers (Belgium)

Case Presentation: Lung CancerSpeaker: A. Luciani (Italy)

Case Presentation: Patient with DementiaSpeaker: M. Hamaker (Netherlands)

Geriatric oncologistPanel: M. Hamaker (Netherlands)

Radiation oncologistPanel: D. Rades (Germany)

Palliative care specialistPanel: T. Saarto (Finland)

Surgical oncologistPanel: M. Reed (United Kingdom)

Clinical oncologistPanel: I. Kunkler (United Kingdom)

Oncology nursePanel: C. Kenis (Belgium)

Palliative carePanel: To be announced


GENERAL SESSIONS GENERAL SESSIONSRARE CANCERS


10:15 - 11:15

Clinical Symposium: Neuroendocrine Tumours Chair: K. Oberg (Sweden)

Chair: L. Bodei (Italy)

Targeted therapies - Exemplified by Radiant 4 TrialSpeaker: J. Yao (USA)

Radiation therapy - Exemplified by NETTER1 TrialSpeaker: L. Bodei (Italy)

Chemotherapy - Exemplified by latest study informationSpeaker: M. Pavel (Germany)

AdVince - antiviral therapy TrialSpeaker: K. Oberg (Sweden)

15:00 - 16:30

Proffered Papers: Sarcomas Presentation of Selected Abstracts

16:45 - 18:15

Clinical Symposium: Sarcoma Chair: R. Haas (Netherlands)


Structured contribution of patients in developing new treatment standards in sarcomas: Examples from chordoma and desmoid tumoursSpeaker: To be announced

Guideline development in rare cancer: a combined patient-physician effort in sarcomaSpeaker: P. Hohenberger (Germany)

Why are we still giving doxorubicin in first line metastatic soft tissue sarcoma?Speaker: W. Van der Graaf (United Kingdom)

Specialist teams or specialised networks for rare cancerSpeaker: To be announced

Discussion


07:45 - 08:45

Multidisciplinary Tumour Board: Neuroendocrine Tumours

Case presentation:

1: Pancreatic NETCase presentation

2: Small bowel NETModerator: P. Hellman (Sweden)

Medical oncologistPanel: D. O'Toole (Ireland)

Surgical oncologistPanel: P. Hellman (Sweden)

Radiation oncologistPanel: L. Bodei (Italy)

Imaging specialistPanel: A. Sundin (Sweden)


Oncology nursePanel: L. Davies (United Kingdom)

THORACIC CANCER


15:00 - 16:30

Proffered Papers: Thoracic Cancer



07:45 - 08:45

Multidisciplinary Tumour Board: Thoracic Cancer

Case presentationModerator: J. Jassem (Poland)

Medical oncologistPanel: W. Eberhardt (Germany)

Radiation oncologistPanel: D. De Ruysscher (Netherlands)

PneumologistPanel: E. Smit (Netherlands)

Surgical oncologistPanel: M. Wouters (Netherlands)

RadiologistPanel: H. Kauczor (Germany)

Nuclear Medicine PhysicianPanel: K. Herrmann (Germany)


Oncology NursePanel: A. Olijve (Netherlands)

10:15 - 11:15

Clinical Symposium: Thoracic Cancer - Trials and Outcome Research that Change Practice

Chair: E. Troost (Germany)

Chair: M. Schuler (Germany)

KEYNOTE-010: Anti-PD-1 anitbody therapy with or without biomarker?Speaker: E. Felip (Spain)

Combined CFRT and SABR in Stage II and III NSCLC with peripheral tumours smaller than 5 cmSpeaker: J.S.A. Belderbos (Netherlands)

Isotoxic Intensity Modulated Radiotherapy (IMRT) in Stage III Non Small Cell Lung Cancer (NSCLC): A feasibility studySpeaker: To be announced

New insights in real-world surgical care for lung cancer patientsSpeaker: H. Schreurs (Netherlands)


10:15 - 11:45

Critical Review: Thoracic Cancer - Critical Review of Presented Trials and Implication in Practice

Chair: J.C. Soria (France)

Chair: B. Van Herk (Netherlands)

Medical oncology perspectiveSpeaker: M. Schuler (Germany)

Radiation oncology perspectiveSpeaker: D. Zips (Germany)

Surgical oncology perspectiveSpeaker: M. Wouters (Netherlands)

What is the value of these new treatments?Speaker: J.C. Soria (France)

Panel Discussion

Medical oncologistPanel: M. Schuler (Germany)

Radiation oncologistPanel: D. Zips (Germany)

Surgical oncologistPanel: M. Wouters (Netherlands)

Molecular pathologistPanel: L. Conradi (Germany)

Oncology nursePanel: A. Charalambous (Cyprus)

Patient advocatePanel: B. Van Herk (Netherlands)


GENERAL SESSIONS GENERAL SESSIONSUPPER GI


07:45 - 08:45

Multidisciplinary Tumour Board: Upper GI - Hepatobillary

Case presentation: High risk liver metastasesModerator: G. Poston (United Kingdom)

Surgical oncologistPanel: C. Verhoef (Netherlands)

Medical oncologistPanel: G. Folprecht (Germany)

Radiation oncologistPanel: R. Sharma (United Kingdom)

RadiologistPanel: To be announced

PathologistPanel: L. Rubbia-Brandt (Switzerland)


10:15 - 11:15

Clinical Symposium: Upper GI Cancer - Trials and Outcome Research that Change Practice Chair: M. Verheij (Netherlands)

Chair: G. Folprecht (Germany)

Management of gastric cancer with low volume metastatic disease (REGATTA trial)Speaker: H.H. Hartgrink (Netherlands)

HPB: Liver limited colorectal metastases (CLOCC and SIRFLOX/FOXFIRE)Speaker: To be announced

CRITICS trial plus ASCO 2016Speaker: E. Jansen (Netherlands)

Long term results of CLOCC trialSpeaker: T.J.M. Ruers (Netherlands)


07:45 - 08:45

Multidisciplinary Tumour Board: Upper GI - Oesophageal Cancer

Case presentation: Non-responders to neoadjuvant therapyModerator: W. Allum (United Kingdom)

Surgical oncologistPanel: B.P.L. Wijnhoven (Netherlands)


Radiation oncologistPanel: K. Haustermans (Belgium)

PathologistPanel: H. Grabsch (Netherlands)

DietitianPanel: C. Shaw (United Kingdom)

09:00 - 10:15

Proffered Papers: Upper GI


10:30 - 11:45

Critical Review: Upper GI Cancer - Critical Review of Presented Trials and Implication in Practice



Medical oncology perspectiveSpeaker: To be announced

Radiation oncology perspectiveSpeaker: To be announced

Surgical oncology perspectiveSpeaker: D. D'Ugo (Italy)

What is the value of these new treatments?Speaker: To be announced

Panel Discussion


Radiation oncologistPanel: To be announced

Surgical oncologistPanel: D. D'Ugo (Italy)

Patient advocacyPanel: To be announced

Oncology nursingPanel: J. Rundgren (Sweden)

UROLOGY


15:00 - 16:30

Proffered Papers: Urology Presentation of Selected Abstracts


07:45 - 08:45

Multidisciplinary Tumour Board: Urology

Case presentationModerator: T. De Reijke (Netherlands)

Medical oncologistPanel: A. Templeton (Switzerland)

Imaging specialistPanel: H.P. Schlemmer (Germany)

PathologistPanel: E. Comperat (France)

Surgical oncologistPanel: S. Joniau (Belgium)

Radiation oncologistPanel: B. Jereczek-Fossa (Italy)

Oncology nursePanel: E. Van Muilekom (Netherlands)

10:15 - 11:15

Clinical Symposium: Urology - Bladder Cancer

Chair: H. Van Poppel (Belgium)

Chair: B. Jereczek-Fossa (Italy)

Standard or extended pelvic lymphadenectomy in treating patients undergoing surgery for invasive bladder cancerSpeaker: S.P. Lerner (USA)

Immediate surgery or surgery after Sunitinib Malate in treating patients with metastatic kidney cancerSpeaker: A. Bex (Netherlands)

Impact of radical prostatectomy as primary treatment in patients with prostate cancer with limited bone metastasesSpeaker: To be announced

Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renalcel carcinomaSpeaker: L. Albiges (France)


10:15 - 11:45

Critical Review: Urology - Critical Review of Presented Trials and Implication in Practice

Chair: C.N. Sternberg (Italy)

Chair: M. Kirby (United Kingdom)

Urology perspectiveSpeaker: N. Mottet (France)

Medical oncology perspectiveSpeaker: L. Albiges (France)

Radiation oncology perspectiveSpeaker: K. Haustermans (Belgium)

What is the value of these new treatments?Speaker: C.N. Sternberg (Italy)

Panel discussion

UrologistPanel: N. Mottet (France)

Medical oncologistPanel: L. Albiges (France)

Radiation oncologistPanel: K. Haustermans (Belgium)

Oncology nursePanel: E. Van Muilekom (Netherlands)

General PractitionerPanel: M. Kirby (United Kingdom)

Patient AdvocatePanel: K. Mastris (Belgium)


GENERAL SESSIONSOUTCOME RESEARCH


13:15 - 14:45

Changing Practice Session: Yes, Data Can Talk Together

Chair: J. Bogaerts (Belgium)

Chair: P. Selby (United Kingdom)

United Kingdom: Public health England, National cancer Intelligence Network (NCIN)Speaker: C. Carrigan (United Kingdom)

EU: Rare Cancer (rarecare Net), high resolution data to support implementation studies: A pilot on head and neck cancerSpeaker: A. Trama (Italy)

Belgium: Quality indicator studies led by KCESpeaker: To be announced

Molecular epidemiology, IARCSpeaker: To be announced

Discussion


11:30 - 12:45

Changing Practice Session: The Value of Cancer Registries Chair: V. Lemmens (Netherlands)

Chair: A. Katalinic (Germany)

Belgium: Innovative methodology to optimise translation of trial outcome to real-world patientsSpeaker: L. Liu (Belgium)

Germany: Population-based quality of life data collection and its impact on daily practiceSpeaker: A. Waldmann (Germany)

Netherlands: The NABON Breast Cancer AuditSpeaker: T. Van Dalen (Netherlands)

United Kingdom: Map the route of cancer diagnosisSpeaker: To be announced

Discussion


10:15 - 11:15

Changing Practice Session: External Validity of Clinical Trials

Chair: L. Liu (Belgium)

Chair: B. Flamion (Belgium)

Modelling effectiveness from clinical trialsSpeaker: M. Egger (Switzerland) Incorporating real-life data into drug development: towards more pragmatic trialsSpeaker: M. Mauer (Belgium)

Panel Discussion Panel: M. Egger (Switzerland) Panel: M. Mauer (Belgium) Panel: To be announced Panel: To be announced Panel: F. Pignatti (United Kingdom) Panel: O. Visser (Netherlands)

HEALTH ECONOMICS IN CANCER CARE


11:30 - 12:45

Changing Practice Session: Affordability of Innovation in Cancer Care: How to Bend the Cost Curve in an Era of Technology Evolution Chair: Y. Lievens (Belgium)

Chair: R. Sullivan (United Kingdom)

Global perspective: Prospects of a multidisciplinary approach to oncology careSpeaker: R. Sullivan (United Kingdom)

Balance between accuracy, outcome and cost in innovative radiotherapySpeaker: Y. Lievens (Belgium)

Challenges and opportunities of personalised therapySpeaker: M. Ijzerman (Netherlands)

The cost of innovation: The regulatory perspectiveSpeaker: To be announced

Minister of Health - The NetherlandsSpeaker: To be announced


11:30 - 13:00

Changing Practice Session: Reimbursement and Market Access to Innovative Oncology Treatments

Chair: M. Ijzerman (Netherlands)


Differences in pricing of novel cancer drugs across EuropeSpeaker: W.H. Van Harten (Netherlands)

Reimbursement versus costs of radiotherapy across Europe: Does it impact access?Speaker: J. Borras (Spain)

Innovative approaches to the reimbursement of innovative treatment modalitiesSpeaker: To be announced

Process of cancer care adoption: Beyond the costsSpeaker: To be announced

Minister of Health - ItalySpeaker: To be announced

Discussion

13:15 - 14:30

Changing Practice Session: Value in Oncology Care Chair: To be announced

Chair: B. Jönsson (Sweden)

Surrogate end-points in oncology: The right way to go?Speaker: To be announced

A global approach to outcome: The magnitude of clinical benefit scaleSpeaker: To be announced

Oncology costs in EuropeSpeaker: To be announced

Value for money in oncology: How to combine information of outcome and cost in a multidisciplinary and multinational environmentSpeaker: B. Jönsson (Sweden)

Discussion


09:00 - 10:00

Changing Practice Session: Equity in Cancer Care: Still a Long Way to Go

Chair: C. Grau (Denmark)


Differences in access to high quality cancer care across EuropeSpeaker: To be announced

From availability to actual and future needs: The example of radiation oncologySpeaker: C. Grau (Denmark)

Essential requirements for quality cancer care: oncopolicy perspectiveSpeaker: A. Costa (Switzerland)

Dealing with the increasing oncology needs across Europe: Cancer care programs as a means to frame challenges in multidisciplinary oncologySpeaker: To be announced

Discussion


ORGANISATION OF CANCER CARE DELIVERY


11:30 - 12:45

Changing Practice Session: Not Every Cancer Centre Should Treat Every Cancer Patient. What's the Evidence?

Chair: M. Wouters (Netherlands)

Quality and/or quantity? Evidence to support centralised complex cancer careSpeaker: J. Borras (Spain)

Cancer centre accreditation: Ensuring equity and qualitySpeaker: S. Oberst (United Kingdom)

How to provide seamless care of the large cancer centres and oncology community practice: The German CML Alliance as a best practice exampleSpeaker: J. Geissler (Germany)

Panel Discussion

11:30 - 12:45

Changing Practice Session: Use of Electronic Tools and Telemedicine in Oncology: "The Doctor Will Skype You Now"



Enhancing cancer patient follow-up care and monitoring using telemedicineSpeaker: To be announced

Patient reported toxicity - Using electronic toolsSpeaker: To be announced

Patient information portals - An innovative approach for involving patients in their own care and reducing the burden on clinical teamsSpeaker: To be announced

Panel discussion on risks and benefits of electronic cancer care delivery


09:00 - 10:00

Changing Practice Session: Lung Cancer Screening: Can We Afford Not to? Chair: To be announced

NLST - Design and survival outcomesSpeaker: To be announced

NELSON Trial - Design and survival outcomesSpeaker: To be announced

System readiness, cost effectiveness for lung cancer screening - A Canadian exampleSpeaker: H. Bryant (Canada)

Panel Discussion

REGULATORY


11:30 - 12:45

Regulatory Session: EMA and HTAs On the Hot Seat

Chair: To be announced From drug approval to access – evidentiary standards, can we fill the gap? Speaker: To be announced

Panoramic view of cancer drug HTA in Europe, present and futureSpeaker: J. Mestre-Ferrandis (United Kingdom)

Case study: Kadcyla in HER2+ breast cancerSpeaker: To be announced

Panel Discussion

Panel: To be announced

16:10 - 17:10

Regulatory Session: Case Studies in Approvals of Targeted Agents: Single-Arm Trials Chair: To be announced

Crizotinib in ALK + NSCLC: Development, EU approval and beyondSpeaker: M. Rothenberg (USA)

Single phase 2 trial design for a subset groupSpeaker: To be announced

Regulatory challenges, opportunities and lessons for the futureSpeaker: To be announced

Panel Discussion Panel: To be announced

17:15 - 18:15

Regulatory Session: Real-life Implementation of Biomarker Information to Inform Treatment and Regulatory Decisions - the PD-L1 Experience

Chair: J. Bergh (Sweden)

Challenges with predictive biomarkers for immunotherapiesSpeaker: To be announced

Implementation of biomarker-driven patient selection into routine pathological diagnosticsSpeaker: W. Weichert (Germany)

Harmonising companion diagnostics: Regulatory experienceSpeaker: To be announced



07:45 - 08:45

Regulatory Session: Patient Involvement in Regulatory Discussions

Chair: J. Geissler (Germany)

The role of patients in the design and support of academic trials for rare cancersSpeaker: To be announced

FDA Patient Advisory GroupSpeaker: To be announced

Patient preference elicitation to design trials and interpret results: Experience with melanoma patientsSpeaker: To be announced



09:00 - 11:00

Regulatory Session: Regulating Innovation in Local Regional Treatment



GENERAL SESSIONSPRIMARY CARE PROGRAMME


10:15 - 11:15

Primary Care Session: The Expanding Role of Primary Care in Cancer Management

Chair: D. Weller (United Kingdom)

The vital role of primary care at all stages of the cancer journeySpeaker: D. Weller (United Kingdom)

Facilitated DiscussionFacilitator: I. Banks (Belgium)

11:30 - 12:45

Primary Care Session: Diagnosing Cancer Early - The Most Effective Strategy to Improve Survival: Current Issues in Screening and Diagnosis

Chair: G. Rubin (United Kingdom)

Introduction by the ChairSpeaker: G. Rubin (United Kingdom)

Reducing diagnostic delaySpeaker: R. Neal (United Kingdom)

Designing better pathways to diagnosing cancer / using guidelines to improve cancer diagnosis and referralSpeaker: To be announced

DiscussionModerator: G. Rubin (United Kingdom)

15:00 - 16:30

Primary Care Session: Optimising Treatment and Management of Cancer Patients and Survivors: The Need for Joined-Up Approaches

Chair: T. Saarto (Finland)

Management of cancer patients in primary care


Multi-morbidity and cancer


Palliative care and end of life

Speaker: S. Murray (United Kingdom)

Discussion

16:45 - 18:15

Primary Care Session: Integrated Models of Cancer Management: Bringing Primary Care and Secondary Care Together

Introduction by the Chair Chair: To be announced

Integrated models of cancer management

Speaker: E. Grunfeld (Canada)

Panel Discussion

Panel: B. Zirbs Savigny (Switzerland)


Panel: D. Cameron (United Kingdom)

Panel: J. Wilkinson (Belgium)


Panel: I. Banks (Belgium)

PATIENT ADVOCACY


10:15 - 11:15

Patient Advocacy Session - Side Effects: Out of Sight Out of Mind


15:00 - 16:30

Patient Advocacy Session: Translating Research into Patient Value

Chair: G. Spurrier-Bernard (France)

Chair: J. Geissler (Germany)

What patients want to know about researchSpeaker: To be announcedPatient centric research design - from theory to practice Speaker: To be announced

Panel Discussion: Is randomisation still ethical?Moderator: B. Ryll (Sweden)Panel: A.M.M. Eggermont (France)

16:45 - 18:15

Patient Advocacy Session: Controversies in Care - Myths and Realities Chair: K. Oliver (United Kingdom)

Chair: W. Tse Yared (Belgium)

Are informed patients and caregivers a threat? - video vignettes and discussionModerator: J. Pelouchova (Czech Republic)

Lost in transition: smoothing the way from paediatric to adult cancer careSpeaker: To be announced

Panel discussion: Coping for caregivers: supporting a loved one's journey through palliative care and end of lifeModerator: To be announcedPanel: K. Oliver (United Kingdom)Panel: J. Pelouchova (Czech Republic)Panel: To be announced

PICTURE


ONCOPOLICY


13:15 - 14:45

Policy Session I: How can Oncopolicy Strengthen Multidisciplinary Practice?



13:15 - 14:45

Policy Session II: Meeting the Challenges of Cross-Border Cancer Care


EDUCATIONAL

FRIDAY 27 JANUARY 2017

08:00 - 12:00

Educational Session: Leadership Programme - Part IModerator: D. Ashton (United Kingdom)

14:30 - 17:00

Educational Session: Leadership Programme - Part IIModerator: D. Ashton (United Kingdom)


07:45 - 08:45

Educational Session: How to Efficiently Run a Tumour Board

Chair: G. Poston (United Kingdom)

Speaker: H. Malik (United Kingdom)

Speaker: L. Lundvall (Denmark)


Discussion

10:15 - 11:45

Educational Immersion Programme: Introduction to Omics and Personalised Medicine (Novice)

Chair: I.F. Tannock (Canada)

Principles of molecular characterisation of tumoursSpeaker: R. Bernards (Netherlands)

How drugs might target tumour mutationsSpeaker: J. Rodon (Spain)

Clinical trials evaluating personalised medicineSpeaker: C. Le Tourneau (France)

Problems that limit personalised medicineSpeaker: I.F. Tannock (Canada)

Discussion

10:15 - 11:45

Educational Session: Can we Afford it? How to Determine Cost Effectiveness

Chair: F. Pignatti (United Kingdom)

How to evaluate cost-effectivenessSpeaker: B. Jönsson (Sweden)

Cost-effectiveness in evaluating new technologySpeaker: C. Uyl de Groot (Netherlands)

Role of cost effectiveness in defining cancer policySpeaker: T. Albreht (Slovenia)

Panel discussion

10:15 - 12:15

Educational Session: Research Opportunities: How to Reach the Stars and Improve Your Career Chair: P. Bonomo (Italy)

Chair: D. Fontein (Switzerland)

Surgical oncology perspectiveSpeaker: S. Evrard (France)

Radiation oncology perspectiveSpeaker: D. Zips (Germany)

Medical oncology perspectiveSpeaker: M. Schuler (Germany)

Translational clinician-scientist perspectiveSpeaker: To be announced

Industry perspectiveSpeaker: S. Galbraith (United Kingdom)

Discussion

11:30 - 13:00

Educational Session: Real World Data: Health Outcomes Research

Chair: J.G. Eriksen (Denmark)

How to explore large databases and correct for biasSpeaker: C. Booth (Canada)

Lessons to be learned from large databasesSpeaker: V. Lemmens (Netherlands)

Extrapolation from trials to real lifeSpeaker: A. Templeton (Switzerland)

Discussion


EDUCATIONAL

11:30 - 13:00

Educational Session: Cancer Imaging: A Key Component of Personalised Oncology

Chair: E.G.E. De Vries (Netherlands)

Appropriate use of FDG-PET in the daily management of solid cancersSpeaker: W.J.G. Oyen (United Kingdom)

Whole body MRI: A shifting paradigm for metastatic bone diseaseSpeaker: A.R. Padhani (United Kingdom)

Using imaging as a tools for improved anti-cancer drug tailoring in prospective clinical trialsSpeaker: G. Gebhart (Belgium)

Discussion

11:30 - 13:00

Educational Session: Recognising and Managing Ethical Challenges in Cancer Care


Ethical behaviour on the oncology team


Ethics of selecting and stopping cancer treatment


Ethical interactions with Pharma

Speaker: E.A. Eisenhauer (Canada)

Panel discussion



Panel: E.A. Eisenhauer (Canada)

Panel: B. Van Herk (Netherlands)

15:00 - 17:00

Educational Session: Collaboration in Oncology

Chair: M. Hutka (United Kingdom)

Chair: B. Sousa (Portugal)

Leading others and the art of negotiationSpeaker: To be announced

Conflict resolution and optimising team performanceSpeaker: To be announced

Workshop Panel: To be announced Panel: C. Taylor (United Kingdom)

15:45 - 18:15

Educational Immersion Programme: Personalised Medicine: From Genomics to Clinical Practice (Advanced) Chair: M. Piccart (Belgium)

Molecular pathologistSpeaker: J.S. Reis-Filho (USA)

Interpreting NGS dataSpeaker: A. Irrthum (Belgium)

Intra-tumour heterogeneity and limits to personalised medicineSpeaker: M. Gerlinger (United Kingdom)

Prospective clinical trials focusing on molecular imaging as a tool for personalised therapySpeaker: A. Van der Veldt (Netherlands)

Implementation of personalised medicine in daily practice: RadiotherapySpeaker: P. Lambin (Netherlands)

Implementation of personalised medicine in daily practice: Medical oncology Speaker: P.G. Aftimos (Belgium)

Implementation of personalised medicine in daily practice: SurgerySpeaker: K. Soreide (Norway)

Clinical trials of personalised medicine: A critical look to the future

Speaker: F. André (France) Discussion

16:15 - 18:15

Educational Session: Evidence-based Management of Cancer in Older Patients

Chair: R.A. Audisio (United Kingdom)

Practical geriatric assessment in older cancer patients

Speaker: C. Kenis (Belgium)

Tailoring cancer surgery to older patients

Speaker: R.A. Audisio (United Kingdom)

Adapting radiotherapy to older patients

Speaker: I. Kunkler (United Kingdom)

Adapting systemic therapy for older patients

Speaker: S. Monfardini (Italy)

Tumour Board: Two cases

EDUCATIONAL

16:45 - 18:15

Educational Session: Tomorrow's Clinical/Practical Applications of Liquid Biopsy

Chair: M. Ignatiadis (Belgium)

Overview of circulating tumour cellsSpeaker: C. Dive (United Kingdom)

Circulating tumour cells: Challenges and opportunities on the path to clinical utilitySpeaker: M. Ignatiadis (Belgium)

Circulating tumour DNA: TodaySpeaker: L. De Mattos-Arruda (Spain)

Potential of microRNAs and new circulating biomarkersSpeaker: G. Sozzi (Italy)

Discussion


07:45 - 08:45

Educational Session: How to Efficiently Run a Tumour Board (Repeated)

For details please refer to sessions scheduled on Saturday

10:15 - 11:45

Educational Session: Can we Afford it? How to Determine Cost Effectiveness (Repeated)For details please refer to sessions scheduled on Saturday

10:15 - 12:15

Educational Session: Acquiring Practical Skills: Designing projects, Effectiveness in Writing, Funding Your Research and Speaking Chair: L. De Mattos-Arruda (Spain)

How to do a systematic review: The first task of any studySpeaker: To be announced

How to design an academic trial and get it funded by PharmaSpeaker: To be announced

Role of foundations in funding academic researchSpeaker: F. Cardoso (Portugal)

How to present your research effectively - In a paper, talk or posterSpeaker: I.F. Tannock (Canada)

Discussion

11:15 - 12:45

Educational Immersion Programme: Introduction to Immunotherapy and the Science Behind it (Novice)

Chair: G. Curigliano (Italy)

Fundamentals of tumour immunologySpeaker: I.M. Svane (Denmark)

Approaches to immunotherapy - What works, what doesn't?Speaker: To be announced

Clinical experience with immunotherapy: How to man-age the side-effectsSpeaker: C. Blank (Netherlands)

Discussion

11:30 - 13:00

Educational Track

Educational Session: Patient Reported Outcomes

Chair: F.A. Peccatori (Italy)

Are PROs ready to be accepted as primary endpoints of clinical trials?


The NCI PRO-CTCAE project


Revisiting ovarian cancer trials using PROs

Speaker: M. Friedlander (Australia)

Panel Discussion



Panel: M. Friedlander (Australia)

Patient advocate

Panel: S. Erdem (Turkey)


EDUCATIONAL

15:00 - 17:30

Educational Immersion Programme: Advanced Course in Immunology and Immunotherapy (Advanced)


The emerging science of tumour immunologySpeaker: L. Zitvogel (France)

Checkpoint inhibitors and biomarkers in clinical practice: Predicting respondersSpeaker: P.A. Ascierto (Italy)

Integration of radiotherapy and chemotherapy in immuno-based treatmentSpeaker: K. Harrington (United Kingdom)

How can we afford these new immunotherapy drugs?Speaker: To be announced

Critical perspective on the future of immunotherapySpeaker: J.B.A.G. Haanen (Netherlands)

Discussion

15:00 - 16:30

Educational Session: Improving Patient Safety in Oncology Chair: R. Canetta (USA) Disclosing and reporting medical errors


Evidence-based methods to improve safety of cancer surgery


Patient centred attention to safety

Speaker: A. Kullberg (Sweden)

Discussion

15:00 - 16:30

Educational Session: Real World Data: Health Outcomes Research (Repeated)

For details please refer to sessions scheduled on Saturday


08:30 - 10:00

Educational Session: Recognising and Avoiding Bias in Clinical Trials

Chair: E.A. Eisenhauer (Canada)

Patient selection, wrong endpoints and biases that limit application of clinical trials

Speaker: E. Meershoek-Klein Kranenbarg (Netherlands)

Spin in the reporting of clinical trials


Under-reporting of harm

Speaker: B. Seruga (Canada)

Lies, damned lies and statistics


Discussion

09:00 - 10:30

Educational Session: Inefficiencies in Cancer Care


Inefficiencies in cancer care


Where to save costs without loss of effectiveness


Efficient use of radiotherapy - Do we always need high-tech and multiple fractions?

Speaker: J. Grau Eriksen (Denmark)

Panel Discussion



Panel: J. Grau Eriksen (Denmark)

Panel: B. Jönsson (Sweden)

EDUCATIONAL

09:00 - 10:30

Educational Session: Practicing Oncology in Countries with Limited Resources

Chair: F. Cavalli (Switzerland)

Matching surgical treatment of cancer with patient expectations

Speaker: Z. Mátrai (Hungary)

Applying ESMO or ASCO guidelines for "value" in selecting cancer treatment


Optimising the role of the oncology nurse

Speaker: K. Lokar (Slovenia)

Discussion

10:15 - 11:45

Educational Session: Evidence-Based Public Health Interventions to Prevent Cancer

Chair: P. Autier (France)

An ethicist's view of screening policiesSpeaker: To be announced

Benefits, uncertainties and costs associated with screening for colorectal cancerSpeaker: I. Lansdorp-Vogelaar (Netherlands)

Effectiveness and cost-effectiveness of HPV vaccinationSpeaker: To be announced

Discussion

44 ECCO2017 - From Evidence to Practice in Multidisciplinary Cancer Care - Advance Programme eccocongress.org

KEY DATES

SUBMIT YOUR ABSTRACT!

LATE-BREAKING ABSTRACTS

Showcase your latest scientific data at ECCO2017 – European Cancer Congress, the multidisciplinary meeting for all cancer types, addressing all oncology disciplines and related healthcare professions.

ECCO2017 will have a direct impact on clinical practice and will gather thousands of oncologists from Europe and around the world. This is your chance to present your data before Europe’s unique multidisciplinary oncology platform.

We are looking for novel and practice-changing phase III trial data as well as real-world outcome data. Reaching a global audience, ECCO2017 has an extensive media programme for scientific media worldwide. Submitting your practice changing data for presentation at ECCO2017 will ensure its global visibility.

Late-breaking abstracts describe the latest advances that will change our daily clinical practice.

Focus is placed on capturing abstracts with ground-breaking and unique data that would have been presented for the first time.

Examples of suitable late-breaking abstracts might include the results of a practice-changing prospective Phase III clinical trial; a Phase II study showing anti-tumour activity in a novel context.

25 APRIL 2016 Abstract Submission Opens

25 AUGUST 2016 Abstract Submission Deadline

23 NOVEMBER 2016 Late-Breaking Abstract Submission Opens

7 DECEMBER 2016 Late-Breaking Abstract Submission Deadline

For the full Call for Abstracts, visit: eccocongress.org/abstracts

Breast Cancer

Multi-ModalityRadiotherapySurgerySystemic Therapy

Rare Cancers: Sarcoma


Central Nervous System


Rare Cancers: NET


Gastrointestinal Malignancies - Colorectal Cancer


Supportive Care and Palliation

Palliative CarePsychosocial AspectsQuality of LifeSupportive Care

Gastrointestinal Malignancies - Upper GI


Outcome ResearchClinical Outcomes Studies Real World DataPatient-Reported Outcomes

Urology


Health Economics of Cancer Cost Studies

Gynaecological Cancer


Health PolicyHealth Care Use & Policy Studies

Haematological MalignanciesRadiotherapySystemic TherapyRadiology

Organisation of Cancer Care Delivery

Head and Neck Cancer


Survivorship

Thoracic Oncology


Screening and prevention

Melanoma


Community Cancer Care

Paediatric Oncology Childhood Cancer


Other

Topic TopicSubtopic Subtopic

ABSTRACT TOPIC CATEGORIES

45

CALL FOR ABSTRACTSCALL FOR ABSTRACTS

46 ECCO2017 - From Evidence to Practice in Multidisciplinary Cancer Care - Advance Programme eccocongress.org 47ECCO2017 - From Evidence to Practice in Multidisciplinary Cancer Care - Advance Programme eccocongress.org 47

Through the generosity of the ECCO2017 European Cancer Congress Sponsors,

• 20 Fellowship Grants are offered to young oncology professionals from countries with lower-middle income economies as per World Bank classification to attend the congress

• 20 Fellowship Grants are offered to young oncology professionals from Eastern European countries

To meet the requirements to be considered for a fellowship grant the applicant should:

• Submit an abstract for the ECCO2017 European Cancer Congress. Applicants whose abstracts have been accepted for an oral or poster presentation at the congress will be considered first.

• Submit the online Fellowship Grant application form ONLY ONCE irrespective of the number of abstracts submitted by the applicant.

• Be under the age of 40.

• Provide a letter of support from the Head of the Department/Organisation stating that the applicant is not the recipient of any other financial support.

• Provide a two page CV (including date of birth).

• Be fluent in English.

The deadline for receipt of applications is 25 August 2016. Incomplete applications will not be considered.

Each fellowship will include:

• Free registration to the congress

• Free accommodation in one of the selected hotels (maximum 3 nights)

• 500 EUR travel grant – to meet the travel expenses from Eastern European Countries

• Reimbursement of travel costs up to 1200 EUR based on an apex return airfare in economy class from countries with lower-middle income economies

• Reimbursement after the congress

FELLOWSHIP GRANTSAPPLICATION

FELLOWSHIP GRANTSAPPLICATION THE DEADLINE FOR RECEIPT OF APPLICATIONS IS 25 AUGUST 2016.

TO APPLY PLEASE COMPLETE THE ONLINE APPLICATION FORM.If you have NOT yet submitted an abstract for the congress go to: www.eccocongress.org

Please note that the Abstract Submission is open until 25 August 2016.

Fellowship applications can only be submitted online. Applications submitted by post, fax or email will not be considered.

Successful applicants will be notified by early November 2016.

On the first day of the Congress (January 27th, 2017), SIOPE will present a highly innovative programme for its community of professionals working in the field of childhood cancers.

Cancer is the biggest threat to children’s lives after safety incidents, and here at this Congress experts from paediatric cancer groups and national societies will share their crucial research results to tackle this major problem.

This SIOPE Society Day will focus on the most demanded and needed educational topics in paediatric oncology. Covering both the latest innovations and the lessons learnt, and building on the existing cooperation with the adult oncology world, this educational session will be extremely informative and useful to illustrate the most effective approaches at the clinical and research levels.

The second part of the Society Day will consist in a SIOPE Policy Session, focusing in particular on possible funding opportunities for the implementation of the SIOPE Strategic Plan ‘A European Cancer Plan for Children and Adolescents’, where the importance of exchange on EU health and research policies and future initiatives of the SIOPE community will be emphasised.

Experiences from multidisciplinary tumour boards in Europe, as well as clinical symposia on the most frequent types of childhood cancers (leukaemia, CNS and brain tumours, sarcomas), on translational approaches and on immunotherapy will also make part of the overall Programme of ECCO2017, making it a not-to-be-missed appointment for all professionals willing to ensure the best possible outcome to children and adolescents with cancer.

The European Cancer Congress ECCO2017 is THE event for all oncological professionals in Europe, with exclusive multidisciplinary sessions illustrating important discoveries from state-of-the-art cancer research studies.

SIOPE Society DayJanuary 27th, 2017

Credits: Attilio Rossetti for SIOPE - the European Society for Paediatric Oncology


THE ESTRO WORKSHOPSAT ECCO2017

Radiation Oncology is one of the main pillars of oncology care. According to evidence-based recommendations, across Europe, around half of all patients diagnosed with cancer would benefit from radiation therapy at some point during the course of their disease. It has however been estimated that in most European countries radiation treatment is provided to only about 60–80% of all patients who should receive it.

The ESTRO symposium focuses on the factors and determinants that impact access, efficiency and quality of radiotherapy, giving an insight on the ESTRO perspective and vision.

Topics discussed by the panellists will include:

Access:• the availability, needs

and sustainability of radiotherapy resources; now and in the future

• safeguarding innovation in radiotherapy, accounting for socio-economic variables

• the organisation of radiotherapy services in the context of cancer control programs in order to improve accessibility

Efficiency:• optimising processes in

radiotherapy

• seeking the optimal balance between outcomes and costs

Quality:• safety through quality

assurance programs in Radiation Oncology

• radiotherapy contribution to the multidisciplinary cancer care approach

• the importance of interaction between doctors and other stakeholders

Aims1. Introduce basic

communication concepts and competence to the European cancer community

2. Help participants to deal efficiently with difficult communication tasks in a way that make them – and the patients – feel better afterwards

Methods• Blend of interactive

lectures, activities in groups of 2–20 and plenary take-homes

• Highly learner-centered, scheduled program adjusted to participants’ needs as we teach

Program themes• Basics of efficient

communication

• Disclosing uncertainty – breaking bad news

• Delivering complex information

• Shared decision-making and follow-up

The workshop comprises four 90-minute modules.

AudienceRadiation Oncologists, Medical Oncologists, Clinical Oncologists, Surgical oncologists, GP’s, nurses, patient organisations and decision makers.

About the lead facilitatorPål Gulbrandsen is a specialist in public health, former general practitioner and editor, and professor of health services research at the University of Oslo.

TOWARDS STATE-OF-THE-ART RADIOTHERAPY FOR EVERY CANCER PATIENT: WHAT IS AT STAKE?

COMMUNICATION IN ONCOLOGY

Oncopolicy Workshop:January 27, 2017

Communication Workshop: January 27, 2017

Chairs:Yolande Lievens, Ghent University Hospital, Belgium Josep M. Borras, University of Barcelona, Spain

Lead facilitator: Pål Gulbrandsen

Co-facilitators: Søren Cold, Clinical Oncologist, PhD and associate professor, University of Southern Denmark. Robert Glynne-Jones, Clinical Oncologist, Mount Vernon Cancer Centre, UK

Three (3) young clinical oncologists can profit from the opportunity to present their novel clinical trial concepts and benefit from expert advice in ‘The Art of Designing Clinical Trials: The Latest in Methods in Clinical Cancer Research’ Workshop scheduled on 30 January 2017.

YOUNG TRIALIST GRANT

SUBMISSION CRITERIA

Candidates must be within 5 years of completion of Residency/Fellowship training in one of the following disciplines:

• Junior physician specialising in oncology;

• Junior clinical professional managing cancer patients (i.e. urologist, gynaecologist, neuro-oncologist, haematologist);

• Junior radiologist or pathologist with a strong involvement in cancer care.

Submit a cancer clinical trial concept which has not been previously written or performed.

• Free registration to the congress

• Opportunity to present in a congress session

• Meet and interact with renowned oncology experts

EACH GRANT WILL INCLUDE:

CLINICAL TRIAL CONCEPT

SUBMISSION DEADLINE: 1 SEPTEMBER 2016

APPLICANTS WILL BE NOTIFIED BY EMAIL REGARDING THE

STATUS OF THEIR APPLICATION IN EARLY OCTOBER 2016.


ESSO37-Advert-210x297.indd 1 15/04/16 09:49

As the regulatory and scientific landscapes evolve, we have entered an era of clinical research transformation. From the integration of translational research and biomarker development to clinically relevant end-points and value based treatments in real life, new challenges have emerged. This is not without impact on the methodology of clinical

Future of cancer clinical research and therapy

research and new forms and methods of clinical studies have emerged. Solution-driven innovation is needed while setting up new quality and multidisciplinary standards. The EORTC session which will be held within the programme of the ECCO2017 congress, will address the principles of the future of cancer clinical research and therapy.

www.eortc.org Contact EORTC Events Office: [email protected]

The EORTC session which will be held within the programme of the ECCO2017 congress

Current Challenges: Future Opportunities

Meet your European colleagues to discuss the

latest developments in oncology nursing.

Details at: www.cancernurse.eu

In collaboration with: www.ecco-org.eu

The European Oncology Nursing Society presents a one day dedicated cancer nursing programme

27 January 2017, Amsterdam Rai, The Netherlands


Twitter hashtag: #ECCOCongress

Accommodation

Amsterdam RAI Hotel Services has been appointed as the official local housing partner for ECCO2017 and is offering hotel accommodation for both groups and individuals.

For all accommodation queries and information, please contact: [email protected] or tel: +31 (0)20 549 1927.

We kindly ask you to contact the appointed local housing partner directly. The congress secretariat cannot provide accommodation-related information or handle any related requests.

Digital Programme

The ECCO2017 programme will be digital only:

• Get an accurate programme at all times, including any last-minute changes

• Create your personalised programme selection

• Find out quickly and easily where you need to go for your chosen session

• Lighten your load: no book to carry around

• Know that you are helping our environment: together we avoid massive paper consumption!

The digital programme is available:

• As a Searchable Programme on our website

• In our Mobile App

Browse and download at eccocongress.org

GENERAL INFORMATION

CONGRESS VENUE

Detailed information about the venue: www.rai.nl

Insurance

The organisers do not accept liability for individual medical, travel or personal insurance. Participants are strongly encouraged to make their own arrangements regarding health and travel insurance.

Language and Translation

The official language of the Congress is English. No simultaneous translation will be provided.

Lunch and Refreshments

Lunch or refreshments are not included as part of the registration fee.

Networking

ECCO2017 guarantees a wealth of networking opportunities. Our OncoHub which replaces the traditional exhibition hall is designed to promote maximum interaction among congress delegates. ECCO2017 is a unique opportunity to exchange ideas with representatives of all oncology professions as well as patient advocates, policy makers and industry. Meet them in the OncoHub, discuss hot topics in interactive sessions and connect with everyone through our dedicated online community platform.

Amsterdam RAIEuropaplein1078 AZ AmsterdamThe Netherlands

Accommodation reservation opens:

1st June 2016

Accommodation reservation deadline: 28th November 2016

Registration will open in April 2016.

Early Rate Deadline: Saturday 27 August 2016

Early Rate Members 399

Early Rate Non Members 599

Early Rate Groups 599

Early Rate Junior Participants 175

Early Rate Emerging Economy 130

Early Rate Nursing Members 250

Early Rate Nursing Non Members 350

Early Rate Patient Advocates 125

Early Rate Payers (Medical insurance non for profit), HTAs, Regulators 150

Regular Rate Deadline: Monday 28 November 2016

Regular Rate Members 550

Regular Rate Non Members 750

Regular Rate Groups 750

Regular Rate Junior Participants 199

Regular Rate Nursing Members 355

Regular Rate Nursing Non Members 475

Regular Rate Patient Advocates 150

Regular Rate Payers (Medical insurance non for profit), HTAs, Regulators 175

Late Rate Deadline: until last congress day

Late Rate Members 899

Late Rate Non Members 1.099

Late Rate Junior Participants 220

Late Rate Nursing Members 460

Late Rate Nursing Non Members 585

Late Rate Patient Advocates 150

Late Rate Payers (Medical insurance non for profit), HTAs, Regulators 175

Society Day Programme

EONS, EORTC, ESO, ESTRO, SIOPE

ESSO 37 Congress Rates can viewed at eccocongress.org/registration

GENERAL INFORMATION – YOUR A TO Z TO ECCO2017

REGISTRATION WILL OPEN IN APRIL 2016Detailed information about how to register and the terms and conditions will be available http://www.eccocongress.org/registration

REGISTRATION FEES ARE THE FOLLOWING:

Primary Care Programme Day Rate 150

€

€

€


Secretariat:ECCO – the European CanCer OrganisationAvenue E. Mounier 83 B-1200 Brussels, BelgiumTel: +32(0) 2 775 02 01Website: eccocongress.org Hashtag: #ECCOCongress

Congress Dates27–30 January 2017

Detailed information about the venue: www.rai.nl

AccommodationFor all accommodation queries and information, please contact: [email protected] or tel: +31 (0)20 549 1927.

Registration Registration will open in April 2016.

Congress Venue Amsterdam RAIEuropaplein1078 AZ AmsterdamThe Netherlands

SUMMARY INDUSTRY CONTACT:

Bruno De ManPhone: +32 2 775 02 04Email: bruno.deman@ ecco-org.eu

Participants registered for the entire duration of the ECCO2017 Congress are entitled to one free public transport ticket giving access to public transport in Amsterdam throughout the event (transportation to and from the airport is not included).

Delegates are encouraged to use public transport as much as possible.

RAI Amsterdam is easy to reach by both public transport or by car and has ample parking facilities on and outside its site. RAI Amsterdam is situated 8 minutes from Amsterdam’s city centre and 15 minutes from Amsterdam Schiphol Airport.

TRANSPORTATION

INDUSTRY OPPORTUNITIES

Showcase your latest scientific data at ECCO2017 – European Cancer Congress, the multidisciplinary meeting for all cancer types, addressing all oncology disciplines and related healthcare professions.

ECCO2017 will have a direct impact on clinical practice and will gather thousands of oncologists from Europe and around the world. This is your chance to present your data before Europe’s unique multidisciplinary oncology platform.

The congress provides you with established, effective activities like Satellite Symposia and, at the same time, it offers you a wealth of innovative opportunities. Among those is our special OncoHub where delegates will meet to network and learn about new developments. You can also benefit from a wide range of advertising and sponsorship options.

We look forward to working with you to identify and secure the items best suited to your objectives for your participation at ECCO2017.

GENERAL INFORMATION

56 ECCO2017 - From Evidence to Practice in Multidisciplinary Cancer Care - Advance Programme eccocongress.org

eccocongress.orgCongress Secretariat:ECCO – the European CanCer Organisationecco-org.eu

Congress Venue:Amsterdam RAIThe Netherlands